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ABSTRACT
Two substituted analogs of 3-amino-2,2-dimethyltetralin, namely
3-dimethylamino-7-hydroxy-2,2-dimethyl-1-tetralone HBr (J) and
3-dimethylamino-7-hydroxy-2,2-dimethyl-1-tetralol (MRSAL) were evaluated
for opioid agonist and antagonist activity using the electricallystimulated guinea pig ileum longitudinal muscle and mouse vas deferens
preparations.

The effects of these compounds in these tissues were

compared to those induced by several opioid prototype agonists at
~

~,

and delta sites (normorphine, dihydromorphine, ethylketocyclaz-

ocine, U-50,488H, beta-endorphin, dynorphin 1-13, leu-enkephalin and
DADLE) and one opioid antagonist (naloxone).
The results of these experiments demonstrated that compound J
inhibited contractions in a concentration-dependent manner as an opioid
agonist and its effects were antagonized by naloxone in both
preparations.

The agonist effects of J were also irreversibly

antagonized by beta-funaltrexamine pretreatment suggesting a preference
for mu receptors.

On the other hand, MRSAL was able to antagonize all

the opioid agonist prototypes in a concentration-dependent manner, but
with varying affinities.
The differential opioid receptor selectivity for compound J was
studied based on:

{i) its agonist potency in guinea pig ileum

longitudinal muscle versus the mouse vas deferens; (ii) its irreversible
antagonism by beta-funaltrexamine in guinea pig ileum; and (iii ) by the

iii

calculation of the apparent dissociation cons tant (Ke) of naloxone for
this agonist in both preparations.

The opioid receptor preference for

MRSAL was based on its potency in antagonizing the opioid agonist
prototypes by calculating its Ke value,
compound J behaved as a

~

Based on these criteria,

receptor agonist while MRSAL had preference

for mu rather than kappa or delta receptors.

iv

"We pharmacologists must acquire
a knowledge of the tools which
we use."
R. Buchheim, 1849

I dedicate this dissertation to
my mother, Francisca Castelo Matos,
who has shown me to be strong
willed and to persevere.
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INTRODUCTION
Pain ia probably the most primitive and most elemental physical and
emotional distress experienced by animals and humans.

Teleologically,

pain functions as an extremely important warning system to alert an
individual that something is wrong and that a state of trauma or disease
exists.

Ylhen pain becomes constant, intense and intolerable, it is

debilitating and both its clinical assessment and management become
necessary.

To date, drug therapy in the management of pain can be

divided into two major categories:

Group I, the nonsteroidal anti-

inflammatory drugs and nonnarcotic analgesics for the treatment of minor
to moderate pain, and Group II, the narcotic analgesic druga for the
treatment of intenae pain.

The firat group of druga ( aapirin, phenyl-

butazone, acetaminophen, ibuprofen, naproxen, fenoprofen, meclofenamate,
indomethacin, sulindac, zomepirac) act peripherally and probably produce
analgesia by blocking or reducing the production of the various
autacoids that activate peripheral pain sensors (Brune and Lanz, 1984;
Kantor, 1984).

The second group of drugs (morphine alkaloids and

synthetic analogs) appear to produce analgesia by interacting with
stereospecific opioid receptors found in the central nervous system and
associated with perception of pain (Chang and Cuatrecasas, 1979; Simon,
1979; Zukin, 1984).
Morphine, the major alkaloid present in the latex from unripe seed
capsules of the opium poppy, Papaver somniferum, was isolated by the

1

2

German pharmacist Seturner in 1803 (Casy and Parfitt, 1986) and has been
used as an analgesic since the nineteenth century.

However, morphine

induces serious side effects, such as smooth muscle spasm and respiratory
depression, in addition to tolerance and physical dependence (Inturrisi
and Foley, 1984) in animals and humans.

At the present time, morphine is

not synthesized commercially so its production continues to be dependent
on the growth of the opium poppy.

Therefore, there has been an intensive

search for a synthetic non-addictive morphine substitute that would
produce minimal tolerance and adverse side effects.

Many chemicals, most

structurally similar to morphine, have been synthesized but, to date, no
single compound is clearly superior to morphine considering all of the
pharmacologic and toxicologic aspects.

Nevertheless, many of these

synthetic analgesics are available commercially or for research use,
e.g., the benzomorphans, meperidine and related 4-phenylpiperidines
(Fries, 1978; Michne, 1984), fentanyl and the 4-anilinopiperidines,
methadone and related 3,3-diphenylpropylamines, benzimidazoles,
tetrahydrioisoquinoline derivatives and the aminotetralins (Casy and
Parfitt, 1986).
Historical Background of
2-Aminotetralins
The aminotetralins are considered to be structural A,B ring analogs
of morphine (Fries and Bertelli, 1981) and structurally they are also
similar to cyclazocine (Figure 1).

The basic structural requirements for

a potent morphine-like agonist are retained in the 2-aminotetralin
skeleton.

These minimum requirements are a tertiary amine, an alpha-

quaternary carbon, a phenyl group connected to the quaternary carbon and
a 2-carbon chain separating the tertiary nitrogen and the quaternary

HO

HO

CH3
CH3

IMorphine I

OH

I

Rt

I

Cyclazocine

I

N""-R2

Rs

I
Figure 1.

R4

R3

2-Aminotetcalin

I

Chemical Structures of Morphine, Cyclazocine and 2-Aminotetralins.

w

4
carbon (Figure 1) (Martinet al., 1969).

Compounds containing the

aminotetralin structure also have the potential for opioid antagonist
activity.
The history of opioid-like aminotetralins begins with the work of
Martinet al. (1969) and Kandeel and Martin (1973) when these
investigators reported several aminotetralins with analgesic activity.
These compounds were tested for analgesic capacity utilizing the widely
used mouse hot-plate method (Eddy and Leimbach, 1953).

The most potent

compounds synthesized by Martin and his group (Martinet al., 1969; Pai
et al., 1971; Kandeel and Martin, 1973) are shown in Table I.

All of

these compounds were less potent than morphine but roughly equivalent in
potency to meperidine.

Compounds IX and 4b were slightly more potent

than meperidine.
A few years later, Reifenrath and Fries (1979) and Fries and
Bertelli (1982) reported aminotetralins with mixed opioid agonist and
antagonist activity (Table II).

Compound 4c displayed only agonist

activity, but was much less potent than morphine and codeine while
compounds 13a and 13b demonstrated mixed agonist-antagonist properties.
As antagonists, these two compounds (3

mg/Kg

intraperitoneally) were able

to cause 100% inhibition of the analgesic effect of morphine using the
rat tail-flick assay (D'Amour and Smith, 1941).

In addition, compound 4b

displayed only opioid antagonist capacity but was much less potent than
naloxone (4b = 33.5 mg/Kg, naloxone= 0.031 mg/Kg).
Unfortunately, very little pharmacological data are available on the
potency and receptor specificity of these compounds since there have been
no antagonism studies reported using naloxone (NX) or some other opioid
antagonist.

5

Table I.

Analgesic Potency of Substituted 2-Aminotetralin Using Mouse
Hot Plate Assay.

Compound

R1

R2

R3

Rlj

R5

ED5o1

IX

CH3

H

CH3

CH3

H

0.02

XII

H

CH2C6H5

CH3

CH3

H

0.06

XIII

CH3

CH3

CH3

CH3

H

0.05

XIV

CH3

CH2C6lis

CH3

CH3

H

0.06

4a

CH3

H

C6H5

CH3

OH

0.04

4b

CH3

H

CH3

C6Hs

OH

0.03

Meperidine

0.05

Morphine

0.005

1Median analgesic activity expressed as mmoles/Kg by intraperitoneal
route.

6

Table II.

Analgesic and Antagonist Potencies of Substituted 2-Aminotetralin.

Compound

R1

R2

R3

R4

ED5o,

4b

Ph

OMe

H

H

Inactive

4c

Ph

OOOCEt

H

H

13a

H

H

Ph

H

9. 1

5.2-15.9)

1003

13b

H

H

H

Ph

6.3

4.3- 9.2)

1003

Morphine
Codeine
Naloxone

17.8 (10 . 9-29.0)

,.,

AD5o2
3 3 • 5 ( 16 • , -6 9 • 7 )
Inactive

o. 8- 1.5 )
__ 4

7.5
0. 031( 0. 0, -0. 09)

1Analgesic ED5 o (mg/Kg) and its 95% confidence interval using mouse
hot plate assay.
2Antagonist AD5 o (mg/Kg) and its 95% confidence interval using mouse
tail-flick assay for antagonism of morphine ( 6 .5 mg/Kg) .
3percent inhibition (3 mg/Kg) shown after the administration of the
ED50 of morphine using mouse tail-flick assay.
4Not reported.

7
Bridged aminotetralins are structurally similar to morphine and the
benzomorphans.

Dezocine, an example of a bridged aminotetralin, has been

evaluated clinically (parenterally) and has been shown to have an
analgesic potency in the morphine range with the usual side effects of
opioids (Casy and Parfitt, 1986).

As an opioid analgesic, this compound

has an unusual pharmacologic profile in animals since it is devoid of
agonist effects on the guinea pig ileum (Casy and Parfitt, 1986).

In

contrast, Greenberg and Ippersiel (1979) reported that dezocine (100 nM)
effectively inhibited contractions antagonized by NX (100 nM) in this
preparation.

While it acts as an opioid agonist in drug-naive animals,

it acts as an antagonist in morphine-dependent animals and precipitates
withdrawal symptoms (Casy and Parfitt, 1986).
The aminotetralins are able to interact with a number of other
pharmacological receptors.

These other actions include:

(~)

marked

dopamine agonist activity in the cat cardioaccelerator nerve assay
(5-hydroxy-6-methyl-2-aminotetralin derivatives; Cannon and Koble, 1980);
(ii) a D-2 dopamine receptor agonist effect because of its ability to
inhibit the release of prolactin from dispersed anterior pituitary cells
(N,N-disubstituted 2-aminotetralins; Beaulieu et al., 1984); (iii) a
direct acting agonist capacity at post-junctional alpha 1-adrenergic
receptors producing vasoconstriction in the isolated rabbit ear artery
preparation (substituted 2-aminotetralins; DeMarinis et al., 1982);
(jy)

mixed adrenergic and dopaminergic agonist actions as well as a

non-opioid analgesic activity not antagonized by naloxone in the mouse
bot plate assay (2-aminotetralin derivatives; Cannon, et
(])

~-adrenergic

Ai., 1980); and

blocking actions in the isolated guinea pig atrial

preparation (N-substituted 2-amino-6-hydroxy-1,2,3,4-tetrahydro-

8
napthalen-1-ol derivatives; Miyake et

~. ,

1983).

One i nteresting derivative of 2-aminotetralin, namely N-methyl-N(beta-phenylethyl)-1,2,3,4-tetrahydro-6-methoxy-4,4-dimethyl-2naphthylamine HCl, has negative chronotropic and inotropic actions in
addition to antifibrillatory properties in the isolated spontaneouslybeating guinea pig atrial preparation (Johnson et
quently, Graeff et

~.

~.,

1970).

Subse-

(1971) demonstrated that this compound has potent

local anesthetic capacity but is devoid of beta-adrenergic blocking
activity.
Qpioid Receptors
During the past decade, several lines of evidence from
pharmacological, biochemical and anatomical studies have accumulated,
suggesting that there are multiple opioid receptors in the central
nervous system and peripheral organs of animals and humans.
well accepted that mg
exist.

~),

It is now

kappa (k) and delta (8) opioid receptors

To a lesser extent, the epsilon (€) and the sigma

(~)

opioid

receptors are also accepted.
Types of Opioid Receptors .

The first evidence for the existence of

multiple opioid receptors came from the pharmacological studies of Martin
et al. (1976) who studied the effects of morphine- and nalorphinelike drugs in the chronic spinal dog.

The authors postulated the

existence of three stereochemically different opioid receptors based on
three different syndromes mediated by these receptors:
syndrome

(~

(~)

the morphine

receptor) producing miosis, bradycardia, hypothermia,

analgesia and indifference to environmental stimuli; (ii) the
ketocyclazocine syndrome (kappa receptor) mediating miosis, sedation and

9

depression of the flexor reflex (analgesia); and (jjjj the SKF-10,047
(N-allylnormetazocine) syndrome (sigma receptor) causing mydriasis,
tachypnea, tachycardia and mania.

All of these effects could be

antagonized by naltrexone, an opioid antagonist, but each required a
different dose level of naltrexone.

Further studies demonstrated that

chronic administration of morphine, ketocyclazocine and SKF-10,047
induced tolerance and qualitatively different abstinence syndromes, but
~

morphine was able to suppress the abstinence syndrome in morphine-

dependent dogs.

ln vivo, kappa drugs can be distinguished from

morphine-type drugs (mu) by their inability to suppress withdrawal
syndrome in morphine-dependent monkeys
1977).

(Martinet~.,

1976; Lord et

~.

Martin (1981) has reviewed this work.

Subsequently, Lord et Ai. (1977) using isolated tissue preparations
(mouse vas deferens and guinea pig ileum longitudinal muscle) extended
the concept of multiple opioid receptors based on the different
sensitivity of these two preparations to opioid agonists (normorphine,
Met- and Leu-enkephalins and ethylketocyclazocine) and their sensitivity
to naloxone antagonism.

It was observed that the opioid receptor

populations in these preparations were not identical since the mouse vas
deferens was about eight times more sensitive to the enkephalins than the
guinea pig ileum.

On the other hand, the mouse vas deferens was less

sensitive to the effects of morphine as compared to the guinea pig
ileum.

Furthermore, it was observed that the enkephalins in the guinea

pig ileum were antagonized as well by naloxone as was normorphine.

This

suggested that in this preparation, both agonists interact with the same
receptor population.

However, in the mouse vas deferens it was necessary

to use 10 times more naloxone to antagonize the effects of enkephalins

10
than for the antagonism of normorphine.

This suggested that in this

assay the enkephalins and normorphine are agonists at different
receptors.

Lord et al. (1977) concluded that, in the guinea pig ileum,

enkephalins interact with the

~

receptor of normorphine and morphine

type agonists, but in the mouse vas deferens enkephalins act on a new
receptor, the delta opioid receptor, while normorphine acts on the
receptor.

~

In addition, based on the sensitivity of naloxone antagonism

against etbylketocyclazocine (3-6 times more naloxone is required to
antagonize this agonist than mg-receptor agonists), Lord et al. (1977)
independently postulated the existence of the kappa receptor originally
proposed by Martinet al. (1976).

In summary, the guinea pig ileum is

said to have mg and kappa receptors while the mouse vas deferens has
delta,

mg

and kappa opioid receptors.

Further pharmacological evidence for the presence of different
opioid receptors in isolated tissues came from experiments using crosstolerance with selective agonists for the different receptor populations
(\.luster et al., 1981a,b; Schulz et al., 1981; Schulz et ..e.J..., 1984).

The

development of tolerance by selective opioid receptor agonists has
differentiated mg and kappa receptors in the guinea pig ileum and delta,
mg and kappa receptors in the mouse vas deferens (Wuster et al., 1981b)
but bas failed to demonstrate delta receptors in the guinea pig ileum
(Schulz et

~.,

1981).

In these studies,

selective~

agonists were

fentanyl, normorphine and D-Ala2,MePbe4,Met(O)ol5-enkephalin (DAGO),
kappa agonists were 5,9-dimetbyl-2'hydroxy-2-tetrabydroflurfuryl-6,7benzomorpban (MR 2034), (5,9-dimetbyl,2'5)-5,9-dimethyl-2'-hydroxy2-(methoxy-propyl)-6,7-benzo- morphan (MRZ) and ethylketocyclazocine
(EKC), and delta agonists were [D-Ala2-D-Leu5]-enkephalin (DADLE) and
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Tyr-D-Ser-Gly-Phe-Leu-Thr (DSThr).

The principle behind this technique

is based on the assumption that if two agonists exhibit cross-tolerance,
they must be acting at the same receptor site.

Furthermore, if there is

no cross-tolerance between two drugs, it means that their effects are
produced by different receptor populations (Wuster et al., 1981a,b).

In

addition, using the cross-tolerance technique, Schulz and Huster (1981)
have postulated the existence of subtypes (isoreceptors) of mg and kappa
receptors in the mouse vas deferens.

In this experiment, sufentanyl and

normorphine (both mg agonists) did not exhibit cross-tolerance to each
other.

MR 2034 and MRZ (kappa agonists) displayed cross-tolerance to

ketocyclazocine and dynorphin, but not to each other.

One, however, must

be aware of the danger of receptor classification based on selectivity by
exogenous compounds.
Pharmacologically active opioid receptors can also be discriminated
from one another by using highly selective irreversible antagonists.
potent opioid receptor alkylating agents have been used:

Two

beta-

chlornaltrexamine (beta-CNA) and beta-funaltrexamine (beta-FNA)--both
derivatives of naltrexone.

Beta-CNA produces an irreversible antagonism

that can be prevented, but not reversed, by naloxone at all opioid
receptor types.

It can block the effects of mu and kappa agonists in the

guinea pig ileum and additionally the effects of delta agonists in the
mouse vas deferens (Takemori and Portoghese, 1985a).

The selectivity by

which beta-CNA irreversibly blocks opioid receptors was mg
delta.

> kappa >

Since beta-CNA irreversibly blocks all opioid receptors, it has

been used for "protection" studies combined with an agonist with a
selectivity for one of the opioid receptors.

For example, in the mouse

vas deferens, beta-CNA has been used with DSLET (an enkephalin analog
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highly selective for delta receptors) to block irreversibly mu and kappa
receptors without touching delta receptors (protected by DSLET).

On the

other hand, beta-FNA is a highly selective antagonist of mu receptors,
blocking the effects of mg agonists in vitro and in vivo without
affecting kappa or delta receptors (Takemori et al., 1981; Takemori and
Portoghese, 1985a).

Therefore , for example, beta-FNA has been used to

deplete mg receptors in the guinea pig ileum, affording agonist access to
the functional kappa receptors.
Other irreversible ligands available (for review see:
Portoghese, 1985a) to label different opioid receptors are:

Takemori and
etonitazene

isothiocyanate (BIT) (Rice et al., 1982) which labels mg receptors,
fentanyl isothiocyanate (FIT)

(Rothman~

al., 1985) and fumaramido

oripavine (FAO) (Rice et al . , 1982) which label delta receptors,
naloxazone and naloxonazine which label mg receptors (Goodman and
Pasternak, 1984) and phenoxybenzamine which apparently has preference for
mg receptors (Kosterlitz et al., 1981).

Recently, the heterogeneity of opioid receptors has been further
extended by the demonstration that the rat vas deferens has epsilon
receptors.

These receptors are specific for beta-endorphin and (to a

lesser extent) to enkephalins (Liao et al., 1981; Sanchez-Blazquez et
al., 1984) .

In this preparation morphine acts as a partial agonist and

is able to antagonize the inhibition of contractions induced by betaendorphin (Liao,

~

al., 1981; Lord et al., 1982; Chang, 1984).

In summary, the opioid receptors pharmacologically found in various
isolated tissue preparations are as follows:

(~)

guinea pig ileum, mg

and kappa , (ii) mouse vas deferens, delta, mu and kappa; (iii) mouse and
rat ileum, delta; (iv) rabbit ileum, delta and kappa; (y) dog ileum,

13

delta

and~;

(vi) rat vas deferens, epsilon; and (vii.) rabbit vas

deferens, kappa (Oka et al., 1980a,b; Wuster et

£1., 1981b; Liao et al.,

1981; Chang, 1984).
Biochemical evidence for opioid receptor multiplicity was only
possible with the development of highly selective ligands for each class
of receptor.

Goldstein et al. (1971) was the first to describe a method

to define stereospecificity for the opioid receptor, separating out the
non-specific binding of ligand to structures such as brain membranes.
Since then,

~'

kappa and delta opioid binding sites have been charac-

terized in the synaptosomal fraction of homogenate preparations from rat,
mouse, and guinea pig brains (Lord et al., 1977; Kosterlitz et al., 1981;
Chang et al., 1979), monkey and human brains (Lord et al., 1982) , toad
brain (Simonet al., 1982), as well as in guinea pig ileum (Creese and
Snyder, 1975; Zukin, 1984).

Guinea pig cerebellum has been shown to be

rich in kappa receptors (Itzhak et al., 1984) and cultured mouse
neuroblastoma or neuroblastoma-glioma hybrid cells have been shown to
have a homogeneous population of delta receptors (Chang and Cuatrecasas,
1979; Chang, 1984).

However, the adenylate cyclase of this latter system

can be inhibited or dually regulated depending upon the time of exposure
by the enkephalins, morphine and other opiate alkaloids (Sharma et al.,
1977; Lord et al., 1982; Chang, 1984).
Opioid binding sites are stereospecific, saturable, associated with
the membrane fraction of nervous tissue and demonstrate high affinity
binding with both opioid agonists and antagonists.

The binding sites

have a pH optimum in the physiological range of 6 .5 - 8. 0 (Simon, 1979 )
and are influenced by temperature and sodium ions (100 mM) (Pert and
Snyder, 1974; Lord et al., 1982).

Interestingly, the effect of sodium

ions on opioid binding has been used to discriminate between agonist and
antagonist binding since in the presence of sodium (100 mM), the binding
of agonists is markedly reduced with little increase or no effect on the
binding of antagonists (Lord et

~.,

1982; Pert and Snyder,

197~).

To date, several selective ligands have been used for demonstrating
the presence of multiple opioid receptors in brain.

In general, the

order of selectivity of radioactively labeled opioids are as follows:

~

receptor, morphiceptin, DAGO (an enkephalin analogue), fentanyl,
FK

3382~

(an enkephalin analogue), syndyphalin, morphine, dihydro-

morphine, normorphine, naloxone; kappa receptor, U-50,488H, dynorphin
1-13 and certain fragments of prodynorphin; delta receptor, DPDPE, DPLPE,
DTLET, DADLE, DSLET (enkephalin analogues with agonist activity) and ICI
154129 (an enkephalin analogue with delta antagonist activity) (Chang,
198~;

Paterson et al., 1984).

labeled enkephalins
does occur.

with~

A high degree of cross-reactivity for most

binding sites in whole brain preparations

The same is observed with kappa agonists such as

ketocyclazocine and ethylketocyclazocine.
both~

This latter agonist binds to

and delta sites with high affinity (Chang,

198~).

Recently, Pasternak (1986) and Goodman and Pasternak (1984)
described a new high affinity site,

1

~ ,

which is irreversibly

antagonized by naloxazone and naloxonazine.

In binding studies, both

opiates and enkephalins bind with highest affinity (Kn
~1

common site.

Once

~1

<1

nM)

to this

sites are labeled with either one of the

antagonists above, mu2 sites are seen as a lower affinity site (Kn

<

10 nM) which can now be labeled by dihydromorphine and other opiates and
also the low affinity delta site can be labeled by DADLE.
physiological significance of these high affinity

~

The

1 sites seems to be
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related to opioid analgesia.

Since naloxazone treatment shifts the

dose-response curve for analgesic effect of morphine, enkephalins and
even beta-endorphin without affecting mY2 sites under certain conditions,
Pasternak (1986) concluded that
These

~1

sites mediate opioid analgesia.

1 sites appear to be involved in supraspinal analgesia, prolactin

~

release, acetylcholine turnover, catalepsy and hypothermia, while spinal
analgesia may be mediated by delta and/or kappa receptors.
dopamine turnover and growth hormone release

are~

In addition,

or delta, sedation

is kappa while respiratory depression and inhibition of contractions of
the guinea pig ileum are mu 2 mediated.
The

~

opioid receptor, originally proposed by Martin et

~.

(1976), is probably not a true opioid receptor but may be the receptor
for phencyclidine (PCP).

In binding studies, it was demonstrated that of

all the opiates tested, only cyclazocine-like drugs were able to displace
PCP from its binding sites and vice-versa.

Behavioral studies also seem

to demonstrate this nnonopioid" characteristic of cyclazocine.

The

psychotomimetic effects of cyclazocine are only partially reversed by
naloxone, indicating that there is a nonopioid component to the effects
of cyclazocine (Zukin and Zukin, 1981).
Localization of Opioid Receptors.

Opioid receptors are distributed

in specific brain areas of all mammals and probably all vertebrates;

however, the distribution is variable among species.

Binding in specific

brain areas as well as the neuroanatomical localization of

~,

kappa and

delta opioid receptors have been well characterized and allow some
correlation with pharmacological data.

Autoradiographic and binding

studies have detected opioid binding sites in brain and spinal cord.
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Different ratios as well as different localizations exist for mu and
delta receptors.

It appears that mg binding is predominant in the

thalamus, hypothalamus, the periaqueductal gray, interpeduncular nucleus,
inferior colliculus, median raphe nucleus, limbic cortex and in the
laminae I and IV of cerebral cortex.

On the other hand, delta sites

occur in the amygdala, nucleus accumbens, olfactory tubercle, pontine
nuclei, laminae II, III and V of cerebral cortex, and diffusely in corpus
striatum and hippocampus.

Opioid kappa sites appear to be concentrated

in the laminae V and VI of cerebral cortex, caudate-putamen, pyriform

cortex, lateral habenulae, bulbus olfactory tubercle, substantia nigra
and in the molecular layer of cerebellum.

In addition,

~~

kappa and

delta receptors are found in lamina VI of cerebral cortex, nucleus
tractus solitarius, vagus nerve, nucleus ambiguous, substantia gelatinosa
of spinal cord, marginal zone and in the laminae I and II of the dorsal
horn (Kuhar and Uhl, 1979; Chang, 1984; Akil et al., 1984; Zukin and
Zukin, 1981; Paterson et

~.,

1984).

Interestingly, the binding sites in

the rabbit cerebellum are almost all of the

~

type, while the guinea pig

cerebellum seems to contain kappa receptors exclusively (Paterson et al.,
1984).
In the brain, these opioid receptors seem to be both pre- and
postsynaptically localized in the neuronal membrane but dominantly
presynaptically (Kuhar and Uhl, 1979).

Biochemical studies have

demonstrated that opioids affect the release of neurotransmitters such as
acetylcholine, norepinephrine and dopamine, thus suggesting that these
receptors on nerve terminals may modulate release of these
neurotransmitters (Kuhar and Uhl, 1979; Hagan and Hughes, 1984).
Chemical lesion studies with 6-hydroxydopamine in striatum neurons
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(Murrin et al., 1980) have suggested that delta Z'eceptors may be
predominantly localized in presynaptic dopaminergic neurons, while mu
receptors seem to be localized in neurons intrinsic to the striatum.
Opioid binding sites have also been detected in the peripheral nerve
system, such as in the neurohypophysis (Falke and Martin, 1985) and
retinas of rat, cow, toad and snake.

The bovine adrenal medulla has

~

and delta receptors (Leslie et al., 1980), and kappa receptors are
present in placental tissue from both human and rats (Paterson et al.,
1984).
In addition, binding studies have demonstrated the presence of
specific opioid receptors in the myenteric plexus of the guinea pig ileum
but not in the longitudinal muscle itself (Creese and Snyder, 1975).
Leslie et al. (1980), reported the presence of two specific binding sites
for [3H]-dihydromorphine (~) and [3H]-D-Ala2-n- Leu5-enkephalin (delta)
in the mouse vas deferens and guinea pig ileum longitudinal
muscle-myenteric plexus membranes, but there are twice as many delta
sites as

~

sites in the former preparation.

So far there is no

information on kappa binding studies in these preparations.

In the

guinea pig ileum myenteric plexus and mouse vas deferens, opioid
receptors are located presynaptically within the myenteric plexus and
nerve terminals of the vas.

Activation of these receptors at low

frequency electrical stimulation causes a reduction in release of
acethylcholine from cholinergic nerve endings in the ileum (Paton, 1957;
Schaumann, 1957; Huidobro-Toro et al., 1981) and a reduction in release
of noradrenaline from sympathetic nerve terminals in the vas deferens
(Illes, 1982; Wuster et al., 1981a).

As a consequence, in both cases the

amplitude of excitatory potentials induced by the stimulation of these
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nerves is depressed.
Physiological Significance of Opioid Receptors.

The physiological

significance of the various opioid receptors in the different areas of
the central and peripheral nervous system is not yet fully understood.
However, it is important to note that these receptors are localized in
brain sites related to pain sensation, pain perception and pain
modulation, such as the substantia gelatinosa of the spinal cord, the
periaqueductal gray, the median raphe, the dorsal medial thalamus and
layer IV of the cortex.

Creese and Snyder (1975) used binding studies in

guinea pig ileum with the myenteric plexus attached and found a high
level of correlation (£

= 0.96,

~

< 0.001), between the ability of

opiates to inhibit [3H]-naloxone binding in homogenates of guinea pig
intestine and in homogenates of rat brain.

In addition, the

pharmacologic potency of opiates to depress the electrically-stimulated
contractions in the ileum correlates well with the affinity of opiates
for receptors in brain homogenates (Creese and Snyder, 1975).
that morphine sites in the ileum

(~

It appears

receptors) resemble those in brain

(Chang and Cuatrecasas, 1979) while enkephalin sites in the brain
resemble the pharmacological receptor in the mouse vas deferens (Lord
al., 1977; Chang and Cuatrecasas, 1979).

~

Therefore, assays using

peripheral nervous tissue such as the guinea pig ileum with the myenteric
plexus attached and the mouse vas deferens are very useful preparations
to predict the opioid analgesic or antagonistic properties of a
compound.

In these preparations, the primary criteria for a compound to

be acting on opioid receptors is the capacity of naloxone to antagonize
the drug-induced inhibition of electrically-stimulated contractions.
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Endogenous Opioids
The discovery that the brain possessed stereospecific receptors for
morphine led scientists to hypothesize that these opiate receptors
interact physiologically with an endogenous substance or substances
produced by the body.

The first report of an endogenous substance with

opioid activity similar to morphine was by Hughes (1975).

Hughes used

the guinea pig ileum longitudinal muscle and mouse vas deferens
preparations and found that extracts from the brains of rabbit, guinea
pig, rat and pig were capable of depressing electrically-induced
contractions in these tissues.

This effect was reversible by naloxone

but not by propranolol, phentolamine, hyoscine, hexamethonium, mepyramine
and methylsergide, suggesting opioid specificity.

The brain extract with

its "naloxone-reversible activity" (NRA) was soon partially purified and
demonstrated to have a peptide nature.

The molecular weight of this

substance was estimated to be around 700 or less and its biological
activity in the vas was blocked in the presence of aminopeptidases.

NRA

occurred in brain areas in different proportions, with the highest levels
found in the striatum, thalamus, pons and medulla.
Subsequently, Hughes et al. (1975) extended this work by studies
done on the amino acid composition of NRA from pig brain and noted that
the enkephalins were the endogenous ligand for opioid receptors.

The

amino acid sequence for the enkephalins was defined as follows:

H-Tyr-

Gly-Gly-Phe-Met-OH (Methionine enkephalin, Met-ENK) and H-Tyr-Gly-GlyPhe-Leu-OH (Leucine enkephalin, Leu-ENK).

It was also observed that

these natural enkephalins were more potent (5-10 times) in vas deferens
than in the guinea pig ileum, and that the Met-ENK sequence was present
in the sequence (61 to 65) of the long peptide beta-lipotropin,
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previously isolated from pituitary glands of sheep, pig and man.
same time, Goldstein (1976) and Cox et

~.

At the

(1976) reported that fragments

61-91 as well as 61-65 of beta-lipotropin (beta-LPH) from ovine pituitary
demonstrated opioid activity antagonized by naloxone in the guinea pig
ileum preparation and that beta-LPH had no effect by itself at
concentrations up to 1o-6M but in higher concentrations could induce a
slow decrease in ileal contractions which could be antagonized by
naloxone.

This effect was said to be a result of breakdown of beta-LPH

to smaller fragments such as beta-LPH (61-91) or beta-LPH (61-65).

This

same group of investigators also reported that beta-LPH (61-91) was more
potent than normorphine in displacing stereospecific binding of
[3H]-etorphine in guinea pig brain homogenates, and that beta-LPH (61-65)
also was able to inhibit binding but with less potency than normorphine.
On the other hand, beta-LPH (1-91) had only a weak effect on binding and
beta-MSH [beta-LPH (41-58)] was completely inactive.

This beta-LPH

(61-91) fragment was later called beta-endorphin (beta-END) (Table III)
and was shown to be also present in the brain.

Beta-LPH (61-65)

structurally corresponded to a peptide reported previously (Hughes et
al., 1975), namely Met-ENK.

In addition, Li et al. (1977) reported the

synthesis and analgesic activity of human beta-endorphin

(B~End).

BH-END was tested in the mouse hot-plate and rat tail-flick assays and
was found to be 17-48 times more potent as an analgesic than morphine
when applied centrally and 3.4 times more potent than morphine when
injected intravenously.
naloxone.

This analgesic effect was antagonized by

B-END was also isolated from rat pituitary (Rubinstein et al .,

1977) and was found to be identical to camel and sheep B-END in its amino
acid composition.

Interestingly,

B~END

has two amino acid residues
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Table III.

Amino Acid Sequence of Endogenous Opioids and Their Source.

Endogenous Opioid

Amino Acid Sequence

Source

Tyr61_Gly-Gly-Phe-Met-Thr-Ser-GluLys-Ser-Gln-Thr-Pro-Leu-Val-Thr Leu-Phe-Lys-Asn-Ala-Ile-Val-LysAsn-Ala-Tyr-Lys-Lys-Gly-Glu91-oH

Brain and
Pituitary

S -Endorphin

Tyr61_Gly-Gly-Phe-Met- • • • -Tyr87-0H

Pituitary

'Y-Endorphin

Tyr61_Gly-Gly-Phe-Met- • • • -Leu77-0H

Pituitary

ct -Endorphin

Tyr61_Gly-Gly-Phe-Met- • • • -Thy76-QH

Pituitary

Dynorphin A

Tyr1-Gly-Gly-Phe-Leu-Arg-Arg-IleArg-Pro-Lys-Leu-Lys-Trp-Asp-AsnGln17-oH

Porcine
Pituitary

Dynorphin B
( Rimorphin)

Tyr1-Gly-Gly-Phe-Leu-Arg-Arg-GlnPhe-Lys-Val-Val-Thr13-0H

Porcine
Pituitary

Met-enkephalin

Tyr1-Gly-Gly-Phe-Met5-QH

Brain

Leu-enkephalin

Tyr1-Gly-Gly-Phe-Leu5-QH

Brain

Dermorphin

Tyr1-D-Ala-Phe-Gly-Tyr-Pro-Ser7-NH2

Frog skin

B-Casomorphin

Tyr1-Pro-Phe-Pro-Gly-Pro-Ileu7-0H

Bovine Milk

Kyotorphin

Tyr1-Arg2-oH

Bovine
Brain
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different from camel beta-endorphin (Be-END):

tyrosine in position 87

instead of histidine and glutamic acid in position 91 instead of
glutamine.

These structural differences do not change its analgesic

activity (Li et al., 1977) .

Furthermore, other opioid peptides such as

alpha-endorphin and Met-ENK were soon isolated from rat pituitaries in
addition to a nonpeptide which was identified by its cross reactivity
with antiserum to morphine and called "morphine-like compound" (MLC)
(Rubinstein~

al., 1977) .

MLC binds to opioid receptors of the mouse

neuroblastoma x glioma hybrid cell line (NG 108-15) in a noncooperative
fashion, much like morphine, naloxone and Leu-ENK

(Blume~

al. , 1977).

Goldstein et al. (1979, 1981) defined the amino acid sequence of a
novel peptide isolated from porcine pituitary a few years earlier (Cox et
al., 1975) which demonstrated opioid activity in the guinea pig ileum
longitudinal muscle and mouse vas deferens preparations .

This peptide

was about 700 times more potent than Leu-enkephalin, 200 times more
potent than normorphine and 50 times more potent than Be-endorphin in the
guinea pig ileum, but only 3 times more potent than Leu-enkephalin in the
vas deferens .

This opioid peptide was named dynorphin by Gol dstein

~

al. (1979) because of its extraordinary potency in these isolated tissue
preparations .

Dynorphin 1-13 is more potent than dynorphin 1-17

(Goldstein et al., 1981).

Its amino acid sequence is shown in Table III.

While several other endogenous opioid peptides have been isolated
from pituitary and brain of various species (Frederickson, 1984), their
discovery is not limited to these tissues,

~.g.,

dermorphin from the skin

of the South American frog Phyllomedusa sauvagei (Broccardo et al., 1981)
and beta-casomorphin from extracts of lyophilized bovine milk (Casy and
Parfitt, 1986).

The amino acid sequences of these endogenous opioids
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are also shown in Table III.
Precursors.

It appears that the endogenous opioid peptides belong

to three chemical families, each deriving from an independent precursor.
The structural sequences of these precursor proteins have been studied
using recombinant DNA techniques (Numa, 1984).

The B-LPH/ACTH precursor

is a large protein (31 kd), also known as proopiomelanocortin (POMC) and
is the source of

~-LPH,

corticotropin hormone (ACTH), B-END,i(-LPH,ot

or B-melanocyte stimulating hormone (alpha or beta-MSH, depending on
species) and corticotropin-like intermediate-lobe peptide (CLIP).

The

isolation and identification of this precursor has been done in both
mouse and rat pituitary (Rubinstein et al., 1978; Frederickson, 1984).
ACTH and B-LPH are the major products of the anterior pituitary while
B-END

and~-MSH

are predominant in the intermediate lobe.

It was originally thought (Austen et al., 1977) that Me t-ENK was
formed from B-LPH and B-END.

However, the observations that B-END and

Met-ENK are differently distributed in brain and pituitary, that they
occur in different neuronal sys tems and that their levels in the brain
increase at different rates of development (Frederickson, 1984), led to
the assumption that enkephalins have an independent precursor.

The

enkephalins precursor i s a 50,000 dalton protein (not yet been purified
to homogeneity) called proenkephalin or preproenkephalin A.

This

precursor contains four copies of Met-ENK and one copy each of Leu-ENK,
Met-ENK-Arg6-Phe7 and Met-ENK-Arg6-Gly7-Leu8.

It was isolated from

chromaffin granules in the adrenal medulla since this organ is a rich
source of enkephalins (Frederickson, 1984).
Finally, prodynorphin (preproenkephalin B) is the precursor for
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dynorphin and neoendorphin.

It was isolated and sequenced from porcine

pituitary and produces alpha/beta-nee-endorphin, dynorphin A (Dyn 1-17,
Dyn 1-13, Dyn 1-8), dynorphin B (rimorphin) and dynorphin B 1-29
(leumorphin).

All these peptides contain a Leu-ENK sequence (Numa, 1984).

Distribution.

Endogenous opioid peptides have been detected in

many animals (reptiles, lizards, fish, rats, rabbits, guinea pigs,
cattle, cats, frogs, mice, monkeys and humans; for a comprehensive
review see:

Olson et al., 1982).

Radioimmunoassay and immunohistochemical techniques have demonstrated that enkephalins and endorphins are independently distributed
throughout the brain (Watson et al., 1978) and peripheral tissues
(Hughes, et al. 1977).

Enkephalins are distributed very diffusely in

the brain and spinal cord while beta-endorphin is present mainly in the
pituitary gland and certain regions of hypothalamus.
Enkephalin immunoreactivity is found in high concentrations in the
globus pallidus, striatum, hypothalamus, thalamus, brainstem nuclei
(nucleus ambiguus, nucleus tractus solitarius, dorsal motor nucleus of
the vagus, nucleus parabrachialis dorsalis, etc.) and dorsal horn of the
spinal cord (laminae I, II, V, VII and X) (Watson et al., 1977).

The

intermediate lobe of the rat pituitary also shows enkephalinimmunoreactivity (Rossier and Bloom, 1982).

In addition, cell bodies

containing both enkephalin-like immunoreactivity and enkephalinergic
nerve fibers have been shown to occur dispersed in the brain.
bodies are found in many brain areas,

~.,

Such cell

caudate nucleus, peri-

ventricular and supraoptic nuclei of hypothalamus, interpeduncular
nucleus, central gray and reticular formation, nucleus tractus
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solitarius, olfactory bulb and tubercle, lateral preoptic and
suprachiasmatic nucleus, amygdaloid nucleus, hippocampus, neocortex,
cingulate cortex, medial nucleus of the optic tract, etc. and laminae II,
III and VII of the spinal cord.

Enkephalin neurons are found in the

hippocampus, parts of the cortex, corpus striatum, parts of the hypothalamus, median eminence, parts of thalamus, reticular formation,
periaqueductal gray, locus coerulens, parabrachial nucleus, raphe nuclei,
nucleus tractus solitarius, motor nuclei of certain cranial nerves and
the substantia gelatinosa of the spinal cord (for comprehensive reviews
see:

Miller and Cuatrecasas, 1979; Rossier and Bloom, 1982; Kuhan and

Uhl, 1979; Frederickson,

198~).

In general, the levels of Met-ENK are

greater than the levels of Leu-ENK and it has been observed that these
two enkephalins occur in separate neuron populations in the globus
pallidus, putamen, caudate nucleus and guinea pig ileum (Frederickson,
198~).

In general, these neurons are characterized by a short projecting

axon, thus suggesting an interneuronal role (Holaday, 1983).

Met-ENK has

also been detected in the cerebrospinal fluid of normal humans and low
levels have been found in cerebral ventricular fluid in intractable pain
patients (Akil et sl., 1978).

Outside the central nervous system, large

levels of enkephalins are also found in the adrenal medulla, pancreas and
endocrine cells of the grastrointestinal tract (Frederickson,
hearts of guinea pig, hamster, pig and monkey (Xiang
et Ai., 1982).

~

al.,

198~)
198~;

and
Lang

Enkephalin-containing neurons are found along the whole

length of the intestine of man, mouse, chicken, monkey, pig, rat, cat,
rabbit and guinea pig.

The highest densities of these fibers are present

in the myenteric plexus and circular muscle layers of rat and guinea pig
intestine along the entire length of the tract (Miller and Cuatrecasas,
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1979;

Hughes~

al., 1977; Frederickson, 1984).

The guinea pig myenteric

plexus also contains a high density of cell bodies of enkephalin neurons
(Frederickson, 1984).

Enkephalin fibers in the intestine are found

around the ganglion cells of Meissner's plexus and occasionally seen in
the circular muscle.

Based on their reactivity to individual antisera,

it appears that most enkephalinergic fibers in the ganglion cells are
Met-ENK neurons and those in the circular muscle layer are Leu-ENK
neurons (Bossier and Bloom, 1982).

In addition, the enkephalins in the

myenteric plexus are synthesized and stored locally in the intestine and
are not derived from the brain or pituitary (Sosa

~

al., 1977).

This

suggests that they have a neurotransmitter or neuromodulator role in this
tissue.
In general, there is a high correlation between the presence of
opioid receptors detected by autoradiography with [3H]-naloxone and the
presence of enkephalins studied by immunocytochemistry in brain areas
such as the habenula, interpeduncular nuclear complex, nucleus tractus
solitarius, parabrachial nucleus, nucleus of the spinal t ract of the
trigeminal nerve, and the dorsal horn of the spinal cord (Akil et

~.,

1984).
Beta-endorphin is also distributed inside and outside the central
nervous system but, in contrast to enkephalins, its highest concentrations are found i n the anterior and intermediate lobes (Bossier and
Bloom, 1982; Frederickson, 1984) of the pituitary glands of rat, sheep,
pig, cow and man, and in the posterior lobe containing the pars
intermedia of bovine pituitary (Ross et al ., 1977).

In the brain, the

highest concentrations of beta-endorphin are found in the hypothalamus
(Bossier and Bloom, 1979), in the preoptic and paraventricular nuclei and
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in the median emnience.

The paraventricular thalamus, periaqueductal

gray, medial amygdaloid nucleus, zona compacta of the substantia nigra,
zona incerta and locus coeruleus also contain high levels of
beta-endorphin (Frederickson,

198~;

Adler, 1980).

Beta-endorphin

immunoreactivity is also present in the limbic system (Olson et al.,
1982).
Cell bodies containing beta-endorphin in the brain are particularly
localized in the arcuate nucleus of the hypothalamus (Holaday, 1983).
These cell bodies send fibers to the median eminence, anterior
hypothalamus, preoptic and periventricular nucleus.

Additional ascending

and long descending fibers project to the periaqueductal gray, reticular
formation, stria terminalis (Frederickson,

198~)

and to brain stem nuclei

such as the nucleus tractus solitarius (Holaday, 1983).
Although the pituitary may be a source for brain beta-endorphin,
several studies have demonstrated that pituitary and brain betaendorphins come from separate origins.

While brain beta-endorphin seems

to originate from hypothalamic neurons in the arcuate nucleus
(Frederickson,
locally.

198~),

pituitary beta-endorphin is probably synthesized

In the pituitary, beta-endorphin immunoreactivity occurs in the

same structures also exhibiting ACTH immunoreactivity and it is
significant that these two peptides come from the same precursor (Rossier
and Bloom, 1982).

In addition to the pituitary, beta-endorphin has also

been found in the pancreas and in human placenta and semen (Olson et al.,
1982).
Like enkephalins and beta-endorphin, dynorphin is also found in the
central nervous system and peripheral organs.

The highest concentration

of dynorphin immunoreactivity is found in the posterior lobe of the
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pituitary in rats, pigs, cattle and toads, but not in humans (Goldstein,
1984).

Cell bodies containing dynorphin are mainly localized in all

hypothalamic nuclei, periaqueductal gray, nucleus tractus solitarius,
parabrachial nucleus, and also found in the amygdala and raphe pallidus
nucleus,

Fibers and terminals of dynorphin neurons are found throughout

the brain.

Highest densities of fibers are present in the substantia

nigra, hippocampal formation, internal capsule and ventral pallidum
nucleus,

Moderate fiber density occurs in the nucleus tractus

solitarius, raphe pallidus nucleus, stria terminalis and accumbens
nucleus.

A few terminals are also seen in the hypothalamus, cerebral

cortex, olfactory tubercle, amygdala, globus pallidus and caudate/
putamen complex.

In the spinal cord, dynorphin neurons are present

superficially in the marginal zone and deeper in the laminae of the
dorsal horn.

Low levels of dynorphin have been detected in the dorsal

root ganglia of rat and rabbit (for review see:

Goldstein, 1984).

In the periphery, dynorphin is present in the whole length of the
gastrointestinal tract, pancreas, heart, lungs, skeletal muscle, ovary,
liver, kidneys and testis and in bovine adrenal medulla (but not rat).
While enkephalins are found in the adrenal medulla mainly associated with
the chromaffin cells containing epinephrine granules, dynorphin is
associated with those containing norepinephrine.

In the guinea pig

ileum, dynorphin immunoreactive fibers are present in the ganglia of the
myenteric plexus and also in the circular muscle layer.

Dynorphin-

containing cell bodies are found in the submucous plexus (Goldstein,
1984).
In addition, Met-enkephalin, beta-endorphin, humoral beta-endorphin
and dynorphin-immunoreactivity have all been detected in circulating
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human blood (Boarder

~sl.,

Physiological Functions.

1982).
The endogenous opioid peptides have been

implicated in several physiological functions and disease states but, to
date, their precise role in regulating bodily function is not completely
understood.

Their most important physiological function probably

involves the states of pain and stress.

The control of pain is achieved

by the existence of an endogenous pain-suppressing system which arises at
the level of the brain stem and descends to the spinal cord (for reviews
see:

Akil et al., 1984; Fields and Basbaum, 1978; Fields, 1981).

Evidence for this endogenous pain-suppressing system came from studies
showing that electrical stimulation of specific brain stem nuclei led to
a reduction in pain response in animals and man.
blocked by naloxone.

This analgesia was

In addition, several types of stress (cold-swim,

food deprivation, intermittent footshock) also induce an analgesia which
is partially antagonized by naloxone.

Both stimulation- and

stress-induced analgesia is accompanied by an increase of endogenous
opioids in blood and brain (for review, see:
Pituitary

~-endorphin

Akil, et al., 1984).

and enkephalins seem to be involved in stress-

induced analgesia (SIA) since hypophysectomy abolishes SIA while the
administration of an enkephalinase inhibitor (thiorphan) potentiates
SIA.

This potentiation is reversible by naloxone (Akil et si., 1984).
Furthermore, the endogenous opioids seem to be involved in the

analgesia induced by administration of placebo (Levine et al., 1978), the
analgesia induced by electro-acupuncture (Sjolund et

sl., 1977) and the

analgesia induced by the physiological stress of pregnancy and labor
(Gintzler, 1980).
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A second physiological function in which the endogenous opioids
appear to have important relevance is in the control of cardiovascular
function during disease, shock and trauma (for reviews, see:
1983; Akil et al., 1984).

Holaday,

In several animal models of shock, spinal

trauma and other cerebrovascular states, the administration of the opioid
antagonists, naloxone or naltrexone, improved survival and circulatory
variables (Holaday et al., 1982; Faden et al., 1982) indicating that the
endogenous opioids may play a role in certain pathophysiological states.
The endogenous opioid peptides are known to affect the secretion of
various pituitary hormones (Ferri et al., 1982) and may be involved in
obesity (Atkinson et Ai., 1985).

There are also reports implicating the

endogenous opioids in behavioral effects (Beaumont and Hughes, 1979;
Olson et

~.,

1982), taste preference (Lynch and Libby, 1983) and in

learning and memory performance (McGaugh et al ., 1982).

Although very

controversial, the endogenous opioids have also been implicated in the
pathogenesis of psychoses and abnormal behavior (Olson et al., 1982;
Copolov and Helme, 1983; Verebey et al., 1978).
Pharmacology of Opioid Receptors
in Guinea Pig Ileum and
Mouse yas Deferens
Originally Paton (1957) established the pharmacologic effects of
morphine in the isolated guinea pig ileum.

Subsequent studies on

morphine and other derivatives by Gyang and Kosterlitz (1966), Kosterlitz
and Watt (1968) and Henderson et al. (1972) were conducted using both the
guinea pig ileum longitudinal muscle and mouse vas deferens preparations.
Following these pioneering studies, the two assays have been widely used
by many researchers as pharmacological tools in determining the opioid
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receptor selectivity of new compounds.

Because these two preparations

have · been demonstrated to be very sensitive to the effects of opioids,
only very small amounts of test compounds are needed for a full
evaluation .

In addition, both agonist and antagonist activity can be

documented using these procedures.

Opioid agonist capacity is measured

by the ability of a test compound to depress electrically-stimulated
contractions and then have the effect reversed by naloxone or some other
opioid antagonist.

The opioid antagonist activity of a given compound is

assayed by its capacity to antagonize the inhibition of contractions
induced by prototype opioid agonists (Kosterlitz and Waterfield, 1975).
Opioid agonists have been shown to reduce acetylcholine release from
cholinergic nerve endings in the guinea pig ileum (Paton, 1957;
Huidobro-Toro

~~.,

1981) and to inhibit the release of noradrenaline

from sympathetic terminals in the mouse vas deferens (Henderson et
1972).

An opioid antagonist

(~.g.,

~.,

naloxone), on the other hand, causes

an increase in the output of acetylcholine released during electrical
field stimulation of the guinea pig ileum at 0.017 Hz (Waterfield and
Kosterlitz, 1975).

This action of naloxone in the ileum is presumed to

be due to its capacity to antagonize the action of the endogenous
enkephalins present in the myenteric plexus-longitudinal muscle.
There are four pharmacological approaches to establish the opioid
receptor selectivity of a new agonist in isolated preparations:
(~)

A comparison of the concentration of the agonist to
depress contractions in the ileum to that required in
the mouse vas deferens.

For example, the enkephalins

are more potent than morphine in the vas deferens and
equipotent to morphine in the ileum; this suggests
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that enkephalins are interacting at the same receptor
site as morphine in the ileum, but at a different
receptor in the vas deferens (Lord et

(11)

~.,

1977).

A documentation of the relative sensitivity of the
agonist to naloxone antagonism by measuring the
apparent dissociation constant (Ke value) for the
antagonist in the same tissue.

Naloxone has been

widely used as the prototype opioid antagonist;
however, this antagonist is not specific for any
opioid receptor but does have its best affinity at
~-sites.

Therefore, low Ke values for naloxone

antagonism suggest that the agonist i s interacting at
~

receptors, whereas high Ke values indicate

interaction with kappa or delta receptors (Lord et
al., 1977; Paterson et
(iii)

~.,

1984).

A checking for selective tolerance induced by an
agonist to a particular receptor type.

For example,

preparations made tolerant to morphine demonstrate
cross-tolerance to other

~

or delta agonists (Schulz et

(1JO

agonists but not to kappa
~.,

1981 ) .

A demonstrat ion of select ive receptor inactivati on by
using alkylating agents such as B-FNA.

This

alkylati ng agent is a selective antagoni s t of
receptors (Goldstein and James, 1984 ) .

~

In the ileum,

B-FNA causes an irreversible blockade of the effects
of normorphine and Leu-enkephalin without affecting
the effects of dynorphin (Huidobro-Toro et
Way, 1984).

~.,

1982 ;
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The opioid receptor selectivity of an antagonist is, in general,
evaluated by its ability to selectively antagonize the effects of

~'

kappa and delta agonists in these preparations

1982c).

The guinea pig ileum contains mainly
~.,

(Lord et

and kappa opioid receptors

1977; Schulz et al., 1981); however, Suet al. (1981) have

also suggested the presence of
preparation.

~

(Yoshimura~~.,

a~

or SKF-10,047 receptor in this

On the other hand, the mouse vas deferens contains three

types of opioid receptors, namely delta, kappa and

~,

since specific

agonists acting at each of these receptors are capable of decreasing
contractions in this preparation (Miller and Shaw, 1983; Schulz et
1984).

~.,

It is important to note that delta receptors are not present in

the ileum and the agonist effects of delta-ligands (enkephalins) in this
preparation are probably due to their interaction at
al., 1977; Paterson et al., 1984).

~

sites (Lord et

The selectivity of synthetic opiates

and endogenous opioids for each of these receptor sites is very
variable.

In both preparations (using the criteria of relative potency

to depress contraction and relative sensitivity to naloxone antagonism),
the most selective mM agonists are:

morphine, normorphine,

dihydromorphine, sulfentanyl, etorphine and oxymorphone .

Their

interaction at other opioid receptors is only about 1% of that at
sites (Chang, 1984; Lord et

~

Al., 1977).

Cyclazocine, EKC and other benzomorphans, as well as U-50,488H, are
generally used as prototypes for kappa receptors; however, in binding
studies (Lahti et Ai. , 1982) it has been demonstrated that 60% of EKC
binding to brain tissue is at
at kappa sites.
high affinity.

~

sites and only 40% of total binding is

U-50,488H seems to bind to kappa receptors only with
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Opioid peptides are agonists at different receptor sites in these
two isolated preparations.

In addition to their high potency and

sensitivity to naloxone antagonism in these tissues (Lord et al., 1977;
Yoshimura et al., 1982a; Sanchez-Blazquez et
demonstration of cross tolerance (Schulz et

£l., 1984a), and the

~.,

1981, 1984) and

selective receptor inactivation with B-FNA or B-CNA (Huidobro-Toro

~

al., 1982; Cox and Chavkin, 1982; Chavkin et al., 1982), studies have
suggested that the dynorphin peptides interact with kappa receptors in
both preparations.

However, the enkephalin peptides and analogues

interact at mg sites in the guinea pig ileum and at delta sites in the
mouse vas deferens (Lord et al., 1977).

On the other hand, beta-

endorphin seems to interact with mM receptors in the ileum and at
additional sites in the mouse vas deferens
1984).

(~

and maybe delta?) (Chang,

Additionally, this peptide could also interact with epsilon

receptors like those in rat vas deferens.

Both Ke values for naloxone

antagonism against beta-endorphin in the rat and mouse vas deferens are
similar (Goldstein and James, 1984).

Beta-endorphin is the only potent

opioid peptide active in the rat vas deferens (epsilon) (Chang, 1984) and
it is inactive in the rabbit vas deferens (kappa) (Oka et

~.,

1980b).

In binding studies, beta-endorphin is able to interact at

both~

and

delta receptors (Paterson et al., 1984).

Therefore, it appears that

beta-endorphin is a potent agonist

delta and epsilon receptors.

at~~

It is interesting to note that receptor selectivity for the
dynorphin peptides varies according to the length of the chain.

Thus,

dynorphins 1-11, 1-13 and 1-17 interact with kappa opioid receptors
(Goldstein and James, 1984; Huidobro-Toro et
Yoshimura et

~.,

1982; Oka

~

al., 1982;

Al., 1982a,b,c) while dynorphin 1-9 exhibits both kappa and
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delta agonist activity in these preparations (Wuster et sl., 1981a;
Yoshimura et al., 1982c).

In addition, smaller fragments of dynorphin

(dynorphin 1-5 and 1-7) seem to activate preferentially delta receptors
(Yoshimura et al., 1982b; Wuster

~~.,

1981a).

The enkephalins (Met and Leu-enkephalin), DADLE and several
Leu-enkephalin analogues, in particular [D-P~n2,D-Peb5Jenkephalin and
I 2-L-PenI 5 ]enkephalin (for review see:
[D-Pen

Corbett et al., 1984), are

very selective delta agonists while N,N-diallyl-Tyr-Aib-Aib-Phe-Leu-Oh
(Aib = alpha-aminoisobutyric acid) (ICI-174,864) is the most selective
antagonist at delta receptors.
Other antagonists with rather selective potency have also been
described.

Two benzomorphan antagonists (Win 44,441 and MR 2266) have

demonstrated relative affinity for kappa rather than
et al., 1982c).

~

sites (Yoshimura

Recently, Portoghese and Takemori (1985) reported on an

even more selective kappa antagonist which is the triethylenedioxy
derivative of beta-naltrexamine (TENA).
Apparently,

the~

receptors in the guinea pig ileum are

pharmacologically different from
(Sayre et al., 1983).
antagonists

of~

~

receptors in the mouse vas deferens

It was demonstrated that two alkylating

receptors, 17-cyclopropyl-methyl-4,5-alpha-epoxy-3,

14-dihydroxy-6-beta-(iodoacetamido)-morphinan and its fumaramate ester,
block morphine effects differently.

While the former compound

irreversibly antagonizes mg receptors in the mouse vas deferens, no such
antagonism exists in the guinea pig ileum.

On the other hand, the

fumarate ester causes irreversible antagonism of morphine (mg) in the
ileum with little or no effect towards morphine in the mouse vas deferens.
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Naltrexone is more potent than naloxone against mu agonists
prototypes in the guinea pig ileum but not in the mouse vas deferens
(Takemori and Portoghese, 1984).

This observation also suggests

that~

receptors are different in these two preparations.
Purpose of Research
The search for new synthetic compounds with selective agonist and
antagonist actions at different opioid receptors has led medicinal
chemists all over the world to design hundreds of new structures.

Their

goal is to find a structure that will produce analgesia without the
undesirable side effects and addiction potential of morphine.

Since the

2-aminotetralins are structurally similar to morphine, these compounds
have the potential for opioid agonist as well as antagonist capacity.
In this research, two new substituted analogues of 3-amino-2,2dimethyltetralin, namely 3-dimethylamino-2,2-dimethyl-7-hydroxy-1tetralone HBr (J) and 3-dimethylamino-2,2-dimethyl-7-hydroxy-1-tetralol
(MRSAL) (Figure 2) were evaluated for agonist and antagonist activity
using the electrically-stimulated guinea pig ileum longitudinal muscle
and mouse vas deferens preparations.

The chemical synthesis of compound

J is fully described in Lippman (1984).

There are many reas ons for

specifically choosing these two tissue preparations:

(1)

These assays are relatively simple to set up and
easy to manipulate pharmacologically.

(ii)

These assays are relatively inexpensive and require
only small amounts of test drugs.

(iii)

Most importantly, these assays are useful in
delineating the opioid receptor selectivity of a new

0~

Br

H~'CH
/ J

CH 3
/
N'-CH3

N'-CHJ
CHJ

HO

HO

II
0

QJ
Figure 2.

OH

H

[MRSAL]

Chemical Structur es of 3-Dimethylamino-2,2-dimethyl-7-hydroxy-1-tetralone HBr (J) and
3-Dimethylamino-2,2-dimethyl-7-hydroxy-1-tetralol (MRSAL).

w

~
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compound due to their high sensitivity to opioids
and because they

contain~'

kappa and delta

receptors.
(iv)

These isolated tissue assays allow one to predict
whether a test compound is an agonist, an antagonist
or mixed agonist-antagonist.

(y)

These assays make it possible to study the potency,
affinity and intrinsic activity of a test compound
free from the complex physiological interrelationships observed in whole animal studies.

In this research, we have attempted to define the agonist/antagonist
potential of two newly synthesized compounds (J and MRSAL).

Agonist

potency was compared to that of opioid prototypes such as normorphine and
dihydromorphine

(~

agonists), ethylketocyclazocine and U-50,488H (kappa

agonists), in addition to the peptides

B~endorphin (~and

dynorphin 1-13 (kappa) and Leu-enkephalin and DADLE (delta
Naloxone was used as the reference opioid antagonist.

delta),
and~.

In addition, the

antagonist activity and receptor selectivity of MRSAL was evaluated by
its ability to antagonize the effects of the agonist prototypes listed
above.

It was hoped that the slight difference in chemical structure

between J and MRSAL and the dramatic difference in pharmacologic activity
might illuminate functional relationships between opioid agonist and
antagonist activity and opioid receptor reactivity.

MATERIALS AND METHODS
Drugs and Chemicals
Sodium chloride, biological grade (NaCl), potassium chloride,
reagent grade (KCl), calcium chloride dihydrate, reagent grade
(CaCl 2 .2H2 0), potassium phosphate monobasic, reagent grade (KH2P04),
sodium bicarbonate, reagent grade (NaHC03 ) and dextrose, anhydrous,
A.c.s. Certified (&-glucose) were purchased from Fisher Scientific
Company (Fair Lawn, NJ).

Magnesium sulfate, reagent grade (MgS04.7H20)

was purchased from J. T. Baker Chemical Co. (Phillipsburg, NJ).
Pyrilamine maleate (Grade 1) and choline chloride (Grade 1) were
obtained from Sigma Chemical Company (St. Louis, MO) and L(-) tyrosine,
A.C.S. Certified, was purchased from Eastman Organic Chemicals
(Rochester, NY).
(~)

N-Normorphine hydrochloride (BM) and dihydromorphine

were purchased from Applied Science Laboratories (State College,

PA) while ethylketocyclazocine methanesulfonate

(~

was obtained from

Sterling-Winthrop Research Institute (Rensselaer, NY) and naloxone
hydrochloride
NY).

(~

was purchased from Endo Laboratories (Garden City,

[D-Ala2, D-Leu5]-enkephalin acetate salt (DADLE) was obtained from

Sigma Chemical Company (St. Louis, MO) and the

~-fumaramate

methyl

ester derivative of naltrexone (beta-FNA) was a gift from Dr. D. Fries
of the University of the Pacific (Stockton, CA).

~Endorphin

(Ba-END),

dynorphin 1-13 (DYN 1-13) leucine-enkephalin (Leu-ENK) and (trans-(dl)3,4-dichloro-N- methyl-N-[2-(1-pyrrolidinyl) cyclo-bexyl]-benzene-
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acetamide) methane sulfonate hydrate (U-50,488H) were generously
supplied by Dr. Nancy Lee (University of California, San Francisco,
CA).
(J)

Compounds 3-dimethylamino-2,2-dimethyl-7-hydroxy-1-tetralone HBr
and 3-dimethylamino-2,2-dimethyl-7-hydroxy-1-tetralol (MRSAL) were

synthesized and donated by D. A. Lippman of Stockton, CA.

MRSAL and J

are racemic mixtures.
All the reference drugs were dissolved in distilled water, while
test compounds J and MRSAL were dissolved in 10% ethanol.

The drugs

were added to the perfusion bath in volumes ranging from 10-100

~1.

Control runs using 10% ethanol alone were performed.
Tissue Preparations
Guinea Pig Ileum Longitudinal Muscle (GPI).

Male white guinea pigs

(350-550 g), obtained from Simonsen Laboratories (Gilroy, CA), were
housed in the animal quarters for one week prior to use and allowed free
access to food (Guinea Pig Diet, Simonsen Laboratories) and tap water.
Animals were sacrificed by decapitation and the abdomen opened
immediately by a midline incision.

The ilea-caecal valve was identified

and the ileum was removed and quickly placed in Krebs bicarbonate
solution at room temperature.

The longitudinal muscle myenteric plexus

was prepared from a 6-cm segment of ileum as described by Kosterlitz et
~.

(1970) using the methods of Suet al. (1981).

portion of the terminal ileum was always discarded.

The last 10- to 15-cm
The 6-cm segment of

ileum was gently slid onto a pipette of 5 mm diameter and the mesenteric
attachment was arranged in a straight line.

The strip of longitudinal

muscle with its adherent myenteric plexus was then separated from the
circular muscle by stroking firmly with a cotton-tipped applicator
(soaked in Krebs solution) into the mesenteric attachment and along the
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whole segment and circumference of the ileum.

By this simple procedure,

the longitudinal muscle was completely separated from the circular
muscle.

The resulting strip consisted of a 6-cm segment of longitudinal

muscle with its myenteric plexus firmly attached.

The tissue was then

transferred to a Petri dish containing Krebs solution and the two edges
of the strip were put in juxtaposition and tied together with silk
thread (Ethicon, size 4-0) to form a loop 3-cm long.

This loop was then

mounted between two platinum electrodes in a 5-ml isolated tissue bath
(Fig. 3) made to our specifications (Steed Engineering, Palo Alto, CA)
containing oxygenated (95% o2 and 5% co2 ) Krebs bicarbonate buffer
solution (pH= 7.1) with the following composition (mM):

NaCl 118.40,

KCl 4.75, CaCl2.2H20 2.54, MgS04.7H20 1.20, KH2P04 1.19, NaHC03 25.00,
Q-glucose 11.10, plus choline chloride 20
0.125

~.

~M

and pyrilamine maleate

The temperature of the bath solution was kept at 37°C by

constant circulation of warm water around the bath using a system of a
reservoir and a circulator (Forma-Temp Jr., Forma Scientific Inc.).

The

muscle strip was connected to a transducer (Grass Force Displacement
Transducer Model FT.03) and maintained under a basal tension of 1.0 g.
This tension had to be continuously readjusted during the initial 15-20
min period in the bath.

The tissue was electrically stimulated (Grass

S44 and S88 stimulators) via two platinum ring electrodes made to our
specifications (see Fig. 4) with square pulses of 0.25 msec duration at
a frequency of 0.1 Hz, using supramaximal voltage (70-80 V).

The

isometric contractions induced by maximal electric-field stimulation
were very regular and consistent and were recorded using a multichannel
polygraph recorder (Grass Model 7B Polygraph).

After mounting, the

preparation was allowed to equilibrate for about 1.3 h with continuous
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Isolated-Tissue Muscle Bath. Cross-section of a jacketed
isolated-tissue bath (5-ml) constructed entirely of glass.
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electric stimulation and washes every 5-10 min.

The tension developed

by the longitudinal muscle ranged from 3.0 -

g.

~.0

In general, three to four strips from the same guinea pig were
mounted in separate tissue baths in order to assess the variability of
tissues from the same animal.
Mouse vas Deferens (MVD).

Male Swiss mice

(30-~0g)

were obtained

from Simonsen Laboratories (Gilroy, CA) and housed in the animal
quarters for at least 1 week prior to use.

The animals were allowed

free access to food (Mouse Chow, Simonsen Laboratories) and tap water.
After sacrifice by cervical dislocation, the abdomen was opened and the
two vasa deferentia were sectioned as closely as possible to the seminal
vesicle using the method of Henderson et

~.

(1972) and then dissected

free of connective tissue and excessive fat.

The seminal content was

expelled by inserting a needle (25 G) into the vas lumen and gently
flushing with Krebs solution.

Each edge of a vas deferens was tied with

silk thread (Ethicon, size 6-0) and the tissue mounted between two rings
of platinum electrodes in a 5-ml isolated tissue bath (Figure 3)
maintained at 37°C and containing oxygenated (95%
bicarbonate buffer solution without Mg2+,
7.0) had the following composition
CaCl2.2H20

2.5~, KH2PO~

L(-)tyrosine 0.3.

(~i):

o2

and 5%

co2 )

Krebs

This perfusion solution (pH =
NaCl

118.~0,

KCl

~.75,

1.19, NaHC03 25.00, &-glucose 11.10 and

One end of the vas was connected to a force

displacement transducer and the resting tension of the muscle was set at
0 . 5 g.

This resting tension had to be continually readjusted for the

first 15-20 min period in the bath.

Washes were made every 5 min.

Isometric contractions were recorded polygraphically after being induced
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by electric-field stimulation delivered to the tissue via the two
electrodes mounted above and below the muscle.

The stimulus consisted

of square pulses of 2-msec duration at a frequency of 0.2 Hz and with
voltage set at 70 V.

The vas preparations were allowed to equilibrate

for approximately 45 min with frequent washes.

Under these conditions,

the tension developed by each vas ranged from 0.2-0.5 g.
All the apparatus and instruments (water bath, isolated tissue
bath, force displacement transducer, stimulators and polygraph) used in
the MVD experiments were identical to those used in the GPI preparations.
Agonist/Antagonist ExPeriments
Quantification of Opioid Effects.

After the preparations (GPI and

MVD) had reached equilibrium, the agonist drug was added to the bath and
left in contact with the tissue until maximal effect had been reached.
Concentration-response curves for all opioid agonist prototypes and for
compound J were established using both the cumulative-dose and "singledose" methods (Kosterlitz and Watt, 1968).

The activity of each

concentration of an agonist was recorded for 3 min with the synthetic
opioids and less than 1-2 min in the case of the opioid peptides.
When the "single-dose" method was used in the GPI, the interval
between doses varied from 15-20 min for NM, DHM, BBIEND and Leu-ENK;
15-30 min for J; 25-30 min for DADLE; 25-35 min for DYN 1-13; 30-50 min
for EKC; and 80-90 min for U-50,488H.

When the cumulative method was

used, the interval between doses was 30 min for all agonists except EKC
(70 min) and U-50,488H (90-150 min).
When employing the MVD preparation, the interval between doses for
all the agonists was 20-30 min.
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At least five different concentrations of the agonist were used in
the construction of each concentration-response curve.

The opioid

agonist activity was measured as the capacity of each drug to decrease
the electrically stimulated contractions.

The concentration of an

agonist producing a 50% inhibition of these contractions was termed the

rc 50

and was calculated from the individual concentration-response

regression lines.
Determination of

pA~

Values for Opioid Antagonists.

In order to

assess opioid activity for each agonist, NX was used as a prototype
antagonist for the opioid receptors and was either incubated for 3 min
before the addition of an agonist or added to the bath at the maximum
effect of that agonist.

On the other band, compound MRSAL was incubated

for 5 min (MVD) and 5-10 min (GPI) before the addition of an agonist,
and this compound was also used to antagonize the decrease in contraction induced by the agonists.

When the antagonist was preincubated,

muscle contractions were constantly recorded for 3-5 min and after
addition of the agonist to the bath, the preparation was either washed
out or challenged with the next higher concentration of the agonist
being tested.

The antagonist potencies of NX and MRSAL against the

opioid agonist prototypes and compound J were evaluated by calculation
of the pA2 values for each antagonist.

For the calculation of a pA2

value, concentration-response curves in the absence and presence of the
antagonists were generated and the best fitting straight lines were
obtained using the least-squares method.

The pA2 values were then

obtained mathematically using the equation A'/A

=1

+ B/KB where B

=

concentration of antagonist used, A = concentration of agonist in the

~7

absence of the antagonist corresponding to observed percent response

= concentration of
instance of pA2 = - log

(obtained from the standard curve) and A'

agonist in

the presence of antagonist.

KB

In this

(Tallarida and Jacob, 1979).
B-FNA ExPeriments.
preparation.

These experiments were done only in the GPI

B-FNA (Portoghese et al., 1980; Takemori et

~.,

1981) was

used in order to assess the opioid receptor selectivity of compound J.
This experiment was done in three steps:

(~)

the agonists NM, DHM, J

and EKC were each added to the bath at a concentration that would give
an approximate 45-60% decrease in contractions and the effects were
recorded until maximum effect or for 3 min (time between each dose
varied from 30-40 min);
incubated for

~5

(~)

B-FNA (51

nM)

was added to the bath,

min while the strip was under continuous stimulation

and then the tissue was washed and allowed to recover; (iii) after
control contractions were regained, the agonists NM, DHM, J, and EKC
were added to the bath at the same concentrations used in step

(~).

In

some experiments, NX and MRSAL were used to antagonize the residual
effect of NM, DHM, J and EKC on these B-FNA-treated strips.
Rate-of-Recovery Experiments
Rate-of-recovery experiments were performed for two reasons:
first, in preliminary experiments it was observed that the opioid
peptides used in this research tended to recover spontaneously after
reaching maximal inhibition; second, one way of measuring opioid
antagonist activity in the GPI and MVD is by calculating the reversal of
contraction induced by the antagonist when added to the bath at the time
of the agonist's maximum effect.

The rate of recovery for BH-END,
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DYN 1-13 and Leu-ENK was calculated at time intervals of 5, 10, 15 and
20 min.

Each rate of recovery was calculated according to the method of

Sanchez-Blazquez et al. (1984a) using the following equation:

% recovery =
\olhere:

Tx

= amount

( Tx - Tal
( Tb - Ta)

X

100

of muscular contraction (mm) at a specific time

interval (5, 10, 15, or 20 min), Ta

= amount

of contraction (mm) after

the agonist had produced its maximum effect and Tb

= amount

of control

muscular contraction (mm) before the agonist was added to the bath.
Rate of recovery experiments were performed only in the GPI.
Tolerance ExPeriments
A few experiments were designed to check if DYN 1-13 could induce
acute tolerance in the GPI.

In our preliminary experiments, it

appeared that with time this peptide lost its capacity to depress the
electrically-stimulated contractions.
Three types of experiments were performed.

In the first experiment,

one concentration-effect curve for DYN 1-13 was done utilizing the
"single-dose" method as described by Kosterlitz and Watt (1968).

The

peptide was added to the bath in increasing concentrations, its effects
recorded for 3 min, and the preparation was washed out.
concentrations of the peptide were used.

Only three

The time between doses was 25

min and the total time for completion of the first concentrationresponse curve was 65 min.

A second concentration-effect curve for the

peptide was then conducted 25 min later in the same tissue under the
same conditions as the first curve.

The total time for the second

concentration-response curve was 60 min.
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In the second experiment, a concentration-effect curve for DYN 1-13
was documented using the cumulative-dose method.

In this case, four

increasing concentrations of the peptide were used.

Each concentration-

effect was recorded for 2 min and the preparation was washed out.

A

second concentration-effect curve was documented in the same preparation
60-80 min later.

During this period of time, the preparation was washed

every 5-10 min.
In the third experiment, a concentration of DYN 1-13 that would
give approximately 50% effect was chosen.

This concentration (1.21

nM)

was added to the bath and left in contact with the tissue for 10 min in
order to check its recovery rate and was repeated at an interval of
approximately 30 min.

The total time for the experiment was 130 min.

Statistical Analysis
Statistical analysis of data was accomplished with a HewlettPackard (model 86B) computer using the Hewlett-Packard HP-83/85 General
Statistics Pac.

Statistical procedures used were:

two-sample

~

test

and the paired-sample analysis for calculating basic statistics and
linear regression on paired data.

RESULTS
Agonist Potencies in Guinea Pig
Ileum Longitudinal Muscle and
Mouse Vas Deferens
All compounds tested demonstrated some capacity for depressing the
electrically-stimulated contractions of both preparations.

The

concentration-response agonist curves were mathematically calculated
using the linear portion and the least-squares method.
shown graphically in Figures 5 and 6.

Results are

The concentrations

(nM)

causing a

50% inhibition of maximum response (IC 5 o) as calculated from the
regression line equation are shown in Table IV.

In the longitudinal-

myenteric plexus preparation of the GPI, the most potent compounds were
the

~

values

agonists EKC, DYN 1-13 and

(nM)

of 1.3, 1.8 and

6.~,

potencies of EKC, DYN 1-13 and
summarized in Table V.

U-50,~88H

(Figure 5) with IC5 o

respectively (Table IV).

U-50,~88H

The agonist

as reported by others are

On the other hand, in the MVD (Figure 6), the

delta agonist, DADLE, was the most potent compound tested with an Ic 50
as low as

(Table IV).

0.1~ nM

MVD, but still more potent
agonist (Leu-ENK).
GPI (Ic 50 values

EKC and DYN 1-13 were less potent in the

than~

agonists (NM, DHM) and the delta

Leu-ENK was far more potent in the MVD than in the

(nM)

of 19.6 for the MVD versus

~08.0

for the GPI).

BH-END, DHM and NM were of intermediate potencies in both preparations
(Figures 5 and 6).
potency of

B~END

There appeared to be little difference between the
in the GPI and in the MVD as was the case for NM and
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Table IV. Agonist Potercy of Te.st an::l :Reference Opioids in the El.ectrically..St.imllate:l GPI an::l t1VD.

GPI

MVD

Opioid
Agonist
N

ICsoa (95% Confidence

Slope( b)

r

N

Limits)

rq,0a ( 95% Confidence

Slope( b)

r

Limits)

1-1·1

300

110.2 (103.2-117.8)

38.6

0.62

112

132.3 (121.6-143.9)

55 .2

0.82

DII1

128

45.1 (40.5-50. 1)

35.8

0.72

30

82.7 (67.5-101.2)

37.5

0.72

EKC

1.35

1.3

(1.2-1 .4)

35.5

0.76

~

55.8

0.92

~0,488H

116

6.4

(5.5-7.5)

27.4

0.67

57

24.4 (19.9-30.0)

28.9

0.85

48.5

0.92

54

48.4 (43.2-54.3)

35.8

0.94

44.4

0.86

70

29.8

0.70

BJr-00
DYN 1-13

60
196

37.0 (33.1-41.3)
1.8

(1.7-2.0)

7.7

8.2

(6.8-8.7)

(6.9-9.7)

l..a,}..EM(

8~

408.0 (366.8-453.8)

43.6

0.86

63

19.6 (17.7- 21 .8)

42.9

0.91

DADLE

80

19.9 (17.6-22.5)

35.6

0.93

48

0. 14 (0. 12-D. 16)

60.5

0.92

34.1

0.74

70

35.9

0.82

J

174

9,624.9 (8,771.9-10,561.1)

areso = concentration (rffl that
:Une a:tuations.

~'OU.ld

16,069.4 (13,962.1-18,494.8)

prcduce 50% inhibition of ma:x:im..ln response as calculated

fran

the respective regression

Ul

w
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Table V.

Agonist Potency of EKC, DYN 1-13 and U-50,488H (Kappa
Agonists) in GPI as Reported by Other Investigators .

Opioid
Agonist

rc 50

EKC

0.57 ± 0.04

Chavkin et al., 1982

0.80 ± 0. 10

Yoshimura et al., 1982a,b

0.87 ± 0.07

Yoshimura et al., 1982c

1 • 10 ± 0.20

Takemori et al. , 1981

1.21 ± 0.18

Oka & al., 1982

1.36 ± 0.24

Portoghese and Takemori, 1985

0 . 34 ± 0.04

Chavkin et al . , 1982

0.85 ± 0 . 09

Yoshimura et al., 1982c

0.70 ± 0 . 06

Huidobro-Toro et al., 1981a

0.70 ± 0.10

Yoshimura et al., 1982b

2.08 ± 0.26

Oka et al., 1982

0.79 ± 0 . 05

Huidobro-Toro & al., 1982

2.20 ± 0.30

Wuster et al., 1981a

2.67 ± 0.76

Portoghese and Takemori, 1985

1.17 ± 0.62

Corbett et al ., 1985

3.60 ± 0 .40

Takemori et al. , 1986

DYN 1- 13

U-50,488H

± S. E.

( nM)

Reference
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DHM.

Nevertheless, each was more potent in the GPI.

The agonist

potencies for these opioid agonists in the GPI and MVD as reported by
other investigators are summarized in Tables V-IX.

In general, the

agonist potencies for the reference opioids compounds used in this study
are in agreement with those reported by others.

However, small

differences in Ic 50 values for DYN 1-13, U-50,488H, BH-END and DADLE in
the GPI were noted relative to those reported in the literature.

In

this study, DYN 1-13 was found to be slightly less potent (IC50

= 1.8)

than what had been reported by Chavkin et
(1982b,c) and Huidobro-Toro

~

~.

(1982), Yoshimura et

£l. (1981a, 1982) (Table V).

~.

However,

Oka et al. (1982) have reported an IC 5o value of 2.08 nM which is in
close agreement with ours.

In addition, the IC 50 value for U-50,488H

(6.4 nM) was found to be slightly higher than that of 2.67 nM reported
by Portoghese and Takemori (1985) (Table V).

On the other hand, BH-EliD

and DADLE were found to have lower IC5 o values (37.0 and 19.9 nM,
respectively, Table IV) when compared to those reported by others
(Tables VI and VII).

In the MVD, there were also small differences in

potencies for DADLE while greater differences were observed for EKC and
DYN 1-13.

DADLE was found to be slightly more potent in this study, an

IC5o 0.14 nM as compared to the estimates of others of 0.30, 0.50 and
1.92 nM (Table VIII).

As shown in Table IX, EKC and DYN 1-13 have been

reported to have lower IC 50 values (0.95 and 3.40 nM) than those found
in this study (EKC 7.7 and DYN 1-13 8.2 nM, Table IV).

A major

discrepancy was observed with the potency of NH in the MVD.

This opioid

agonist was found to be only slightly less potent in the MVD as compared
to the GPI (Ic 50

= 132.3

MVD and 110.2 nM GPI, Table IV).

In addition,

this agonist was found to have far lower Ic50 values (132.3 nM) in the
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Table VI.

Opioid
Agonist

NM

DHM

BH-END

Agonist Potency of NM, DHM and BH-END (Mg Agonists)in GPI as
Reported by Other Investigators.

rc 50

± S. E.

(nM)

Reference

79.0 ± 9. 1

Su et al., 1981

9!1.0 ± 9 . 0

Yoshimura et al ., 1982b

108 . 0 ± 16.0

Yoshimura et al., 1982c

95.0 ± 9.5

Chavkin et al . , 1982

72.8 ± 17.7

Waterfield et al. , 1977

90.0 ± !1.0

Huidobro-Toro et al., 1982

62 . 0

Creese and Snyder , 1975

38.7 ± 5.5

Leslie et al. , 1980

7!1.0 ± 2.0

Lee .£1 al., 1982

70.0 ± 2.0

Yoshimura et al ., 1982a

75.0 ± 6.0

Waterfield et al. , 1977

62 . 0

Paterson et al. , 198!1

60.0

Broccardo .£1 al. , 1981
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Table VII.

Agonist Potency of Leu-ENK and DADLE ( Delta Agonists) in GPI
as Reported by Other Investigators.

Opioid
Agonist

rc 50

Leu-ENK

319.0 (252.7-385.5)1

Sanchez-Blazquez et al., 1984a

613.0 ± 48.0

Yoshimura et al., 1982a

656.0 ± 90.0

Yoshimura et al . , 1982c

675.0 ± 85.0

Huidobro-Toro

~

463.0 ± 59.0

Waterfield

al., 1977

250.0 ± 20.0

Lee et al. , 1982

220.0 ± 36.0

Chavkin et al., 1982

303.0 ± 35 . 0

Fournie-Zaluski et al., 1981

970.0 ±150.0

Broccardo e t al., 1981

213.0 ± 40.0

Takemori et al. , 1986

DADLE

± S.E.
( nM)

Reference

~

al., 1982

41.2 ±

5.0

Roques et al., 1982

33.0 ±

3.7

Lee et al., 1982

47.8 ± 1!.4

Kosterlitz et al., 1980

26.6 ± 7.3

Leslie .ll al. , 1980

18.2 ± 3 .9

Takemori et al., 1986

1IC5o (95% confidence interval)
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Table VIII .

Agonis t Pot ency of DADLE and Leu- ENK ( Delta Agonists) in the
MVD as Reported by Other Investigators.

Opioi d
Agonist

I C50 ± S.E .

DADLE

0. 85

Sanchez- Bl azquez et a l. , 1983

0.30 ± 0. 05

Lee et al. , 1982

0. 50 ± o. o9

Roques et al. , 1982

0. 2l! ± 0.10

Portoghese and Takemori , 1985

1. 92 ± 0. 08

Miller and Shaw, 1983

( nM)

O.l!

Leu- ENK

± 0. 05

Refer ence

Wuster et al., 1981a

0. 35

Schulz et al. , 198l!

0. 54 ± 0. 09

Kosterlitz et al. , 1980

O.l!2 ± 0.04

Lesl ie et al ., 1980

0. 31 ± 0.1 8

Takemori et al. , 1986

21. 4

± 3. 3

7. 8 ± 0.8
7. 2

± 0. 5

Lord et al. , 1977
Waterfield et al., 1977
Lee et al. , 1982
Sanchez-Blazquez et al., 1983

9.8
8. 2

± 1.6

Fournie-Zal uski et al . , 1981

29.2

± 3.2

Broccar do et al. , 1981
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Table IX.

Agonist Potency of Several Opioids in the MVD as Reported
by Other Investigators.

Opioid
Agonist

IC50 ± S. E.

NM

231.3

Sanchez-Blazquez et al. , 1983

440.0 ± 42.0

'1-laterfield et al., 1977

181.0 ± 29.0

Miller and Shaw, 1983

360.0

Schulz et al., 1984

156 . 0 ± 14.0

Leslie et al., 1980

DHM
BH-END

Reference

(nM)

Sanchez-Blazquez et al., 1983

81.7
80.0

±

1. 2

Lee et al., 1982

53 . 0 ±

4.0

Waterfield et al., 1977

40.0
EKC

±

1.7

Kajiwara et al., 1986
Sanchez-Blazquez g

3.40
2.2

U-50,488H

Sanchez-Blazquez et al., 1983

0.95
6.06

DYN 1-13

Paterson et al., 1984

± 0.3

17.9 ± 7.8

al . , 1983

Wuster et al. 1 1981a
Takemori et al., 1986
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MVD than those reported in Table IX:

IC 5 o values of 231. 3 nM (Sanchez-

Blazquez et al., 1983), 440 nM (Waterfield e t al., 1977), and 360 nM
(Schulz et al., 1984).
Clearly, compound J was the least potent of all the agent s tested.
In both preparations, J was consistently able to inhibit the
electrically-stimulated contractions in a dose-dependent manner, but it
had little agonist capacity (Figures 5 and 6).

As reported in Table IV,

the Ic 50 value for J in the GPI was 9,624.9 and in the MVD 16,069.4 nM.
This indicates that J is somewhat more potent in the former preparation.
The inhibition of contraction produced by J showed a fast onset of
action reaching maximum effect in about 3 min in the GPI and less than
2 min in the MVD (Figures 7 and 8).

The maximum agonist response

demons trated by J was about 75% in the GPI and 68% in the MVD.
In general, the opioid peptides demons trated a greater maximum
agonis t response (%) than the non-peptides compounds.

One exception was

seen with Leu-ENK in the GPI which displayed only about 70% maximum
agonis t activity.

In addition, in both preparations , the opioid

peptides had much steeper slopes than the other agonists (Table IV and
Figures 5 and 6).
Effects of Opioid Ant agonists
The effects of NX on the electrically-induced contractions of the
GPI and MVD are shown in Table X.

In the GPI, this compound

demonstrated poor agonist activity, producing a maximum agonist response
of about 7% at concentrations of 352 nM, and no agonist response but a
3% increase in muscular contractions at concentrations of 704 nM
(Table X).

In the MVD, NX also demons trated poor agonist activity,

produc ing a maximum res ponse of about 9% (Ta bl e X).
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Table X.

Effects of ~~ on Electricall y-Induced Muscul ar Contractions
of GPI and MVD.

Effect (%)1

Concentration

GPI2

MVD2

(nM)

N

2.8

4

+2.13

±

0.31

NT

5.5

4

+2.67

±

0.50

NT

11.0

6

+ 1. 75 ± 0.65

NT

22 . 0

4

+3.87

±

0.86

NT

44.0

7

+4.65

±

0. 97

NT

88.0

18

+3.53

±

0.67

8

+ 1. 75 ± 1.08

176.0

29

+4. 41

±

1.36

12

+7 .09 ± 1.53

352 . 0

13

+ 7. 45 ± 1. 48

704 . 0

29

t 2. 88 ± 1. 05

N

1Effects of NX were recorded for 3-5 min.
2Results are expressed as Mean ± S.E.
NT

= not

tested .

NT
6

+9 .33 ± 1. 11
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On the other hand, compound MRSAL caused an increase in the
electrically-stimulated contractions of GPI in concentrations up to
425

~(Table

XI).

This increase in muscular contraction was fast in

onset--reaching maximum effect in about 3 min and sustained for as long
as 15 min.

At concentrations ranging from 4.2 to 425

~,

this compound

demonstrated a complete lack of agonist activity in the GPI.
with higher concentrations of 850

~,

However,

(one run only), MRSAL showed some

capacity for depressing muscular contractions in this preparation.

This

decrease in contractions was slow in onset and reached maximum effect
about 8 min after introduction to the tissue.
response observed was 76.32% (Table XI).

The maximum agonist

In contrast, in the MVD, MRSAL

caused both a decrease and an increase in the muscular contractions at
all concentrations tested (Table XI).

In general, the increase in

contraction in this preparation had a very fast onset of action reaching
maximum response in less than 1 min.

The decrease in contractions,

however, was relatively slow in onset and reached near-maximum response
about 5 min after starting incubation.

In most cases, a biphasic effect

was seen with a very fast increase (30 sec) followed by a slow decrease
in contractions.

The percent effect reported in Table XI corresponds to

the effect seen 5 min after the start of incubation.

Testing of the

vehicle, 10% ethanol (0.1 ml) produced only small decreases in
contractions (about 1%) in both preparations (Table XI).
Opioid Agonist Effect of Compound J
Compound J behaved as an opioid agonist in that it consistently
inhibited the muscular contractions of the GPI and MVD in a dosedependent manner and the effects could be antagonized by NX.

J

was
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Table XI.

Effects of MRSAL on El ectricall y-Induced Muscular
Cont r actions of GPI and MVD.

Concentration
(JI-M)

Ef fect (%) 1
GPI2

N

o. .ljO

N
.lj

MVD2

.IJ .2

30

t 0. 62 ±

8.5

21

t 2 . 57 ± 0. 32

NT

21 . 2

91

t 4. 51 ± 0.27

NT

42 . 5

19

t

3. 19 ± 0. 54

36

+ 6. 16 ± 2.03

85 . 0

55

t

9.88 ± 1 • 11

31

t 11.92 ± 4.19

170.0

7

t 11 . 27 ± 1. 19

18

t 12 . 29 ± 5. 14

425 . 0

3

+17 .1 4 ± 2. 34

NT

+ 76 . 32

NT

850 . 0
Vehicl e3

10

+ 1.37 ± 0. 53

10

+18 . 77 ± 3. 47

+ 1. 05 ± 0.26

1Effect s of MRSAL were recorded for 3 , 5 and 10 min i n GPI and 5 min in
HVD.
2Resul t s are expressed as Hean ±

s. E.

3vehicle- 0.1 ml of 10% ethanol in 5
concentration.
NT = not tested .

ml

bath= 0. 2% ethanol final bath
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completely and reversibly blocked by NX at concentrations of 88 and
176 nM.

In both preparations, this blockade was effective whether NX

was added after the agonist (Figures 7 and 8) or incubated (3 min)
before J (Figures 9 and 10).

In addition, Figures 9 and 10 show that J

was also antagonized by MRSAL in the GPI and MVD.
Antagonist Property of B=FNA in
Guinea Pig Ileum Longitudinal
Muscle
In order to delineate the opioid receptor selectivity for the
agonist effects of J, B-FNA was used as an irreversible antagonist of
the

~

receptors.

prototypes

of~

In this experiment, NM and DHM were chosen as the
and EKC of kappa opioid receptors.

Figure 11 shows the

antagonist effect of B-FNA on the effects of NM, DHM, EKC and J on GPI.
B-FNA produced an irreversible antagonism on the effects of NM, DHM and
J (E

< 0.001).

However, B-FNA (51 nM) also demonstrated significant (E

< 0.01) antagonism on the effects of EKC.
The antagonism by B-FNA of NM, DHM and J effects was time dependent.
B-FNA had to be incubated for 45 min in order to produce significant
antagonism.

This antagonism was irreversible since NM, DHM and J were

unable to cause an effect even after the preparation had been washed
thoroughly for more than 20 times and the effect persisted throughout
the experiment (450 min).

However, B-FNA did not produce 100%

antagonism of NM, DHM and J.

Therefore, NX and MRSAL were tested to

antagonize the residual effects of these agonists on these B-FNA treated
preparations.

It was found that NX (176

nM)

was able to antagonize the

residual effect of NM by 100% and J by 98.3 ± 0.8% (mean± S.E., N = 3).
In addition, MRSAL (85

~M)

antagonized these agonists by (% mean± S.E.):

Figure g.
When x
J
J
J
J
J

Agonist Capacity of J and Its Antagonism by NX and MRSAL in the GPI.

= log

concentration and y

(e) 9. 6 J-l·M,
in presence
in presence
in presence
in presence

3 4. 1 ( r =
of MRSAL,
of MRSAL,
of MRSAL,
of NX, 88

= response,

the calculated IC 50 and slope C.b.) values are:

0. 7 4, N = 17 4)
8.5 ~M (•) 15.2~M, 36.0 (r = 0.95, N = 35)
21.2 1-'-H (•) 37.1 p.M, 33.5 (r = 0.93, N = 49)
42.5 JLM ('"') 52.9 p.M, 35.1 (r = 0.93, N = 43)
nM (~) 212.5 ~M, 38.8 (r = 0.90, N = 57)

Clear points (o, v, <1 ) were not used in linear regression.
Please note: Concentrations are in~.

68

..
,...:

N

--

rPf"i

0'1

c

......
~

:r::

~

pt')

.......

~

·-ca

c::

0

Ll'!

-.J

L..

-.J

c::
Cl.)

u

.
.Q

c::
0
u
c::

·-ca
0

~

.c

::::7

N
pt')

0
0

-

0

cc
(X)

0

tO

suon:n~J1UOJ P81B(OW~1S

AflB:>JJ1=>at3 JO uonJQJ4UI

0

u

c::

Figure 10.
When x

= log

Agonist Capacity of J and Its Antagonism by NX and MRSAL in the MVD.
concentration and y

=

= response ,

the calculated

=

rc 5 o

and slope (R) values are:

J ( e ) 16.1 ~M, 35.9 (r
0.82, N 70)
J in presence of MRSAL, 42.5 ~M (•) 6.4 pM, 30.9 (r
0.82, N 31)
J in presence of NX, 176 nM (•) 78.0 ~M, 28. 1 (r
0.90, N 33)

=

Clear points (o, 6) were not used in linear regression.
Please note: Concentrations are in f&lf.
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Figure 11.

Antagonist Property of B-FNA on the Effects of NM, DHM, EKC and J in the GPI.

Concentrations (nM) used before and after B·-FNA treatment were:
N = 13), EKC 2.5 (N:: 13), J 15,930.0 (N:: 10).
Level of significance from control before B-FNA treatment:

NM 156.9 (N

= 14),

L< 0.01 (**),X< 0.001

DHM 55.7

(***).
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NM 99.8 ± 0.21 (N = 6), DHM 99.2 ± 0.4 (N = 3) and J 98.5 ± 0.5 (N = 6),
Moreover, MRSAL (170

~M)

produced a 56.7 ± 1.0% (N = 3) antagonism of

the residual effects of EKC on the B-FNA treated ileum,
B-FNA also possessed agonist activity, producing a decrease in the
electrically- induced contractions of 69.1 ± 1.0% (mean± S.E., N =50).
This effect was fast in onset of action (reaching maximum in less than
2 min) and persisted for the period of incubation (45 min).

The agonist

effect of B-FNA was reversible; however, it took about 150 min, with
washes every 5-10 min, for approximately 80% recovery of control
contractions,
Opioid Antagonist Property of MRSAL
in Guinea Pig Ileum Longitudinal
Muscle and Mouse Vas Deferens
In contrast to compound J, compound MRSAL demonstrated significant
opioid antagonist activity in both preparations in a manner similar to
that of NX,
specific,

The antagonism was concentration dependent, reversible and
MRSAL was able to antagonize the agonist effects of the

opioids used as reference compounds (NM, DHM, EKC, U- 50,488H, BH-END,
DYN 1-13, Leu-ENK and DADLE) and also the test opioid agonist, compound

J.

In addition, MRSAL antagonism was effective whether it was incubated

(3, 5 and 10 min) before or added after the agonist,

Figures 12 to 27

illustrate MRSAL antagonism when incubated before the opioid agonists in
the GPI and MVD.

In general, there was a parallel shift of the

dose- response curve to the right in a competitive fashion and an
increase in IC 50 values for all agonists tested.

However, there was

some loss of parallelism when MRSAL was used in higher concentrations in
the GPI (Figures 14, 16, 20 and

2~).

In this preparation, the most

effective displacement of the concentration- response curve by MRSAL was

Figure 12.
When x
NM
NM
NM
NM

= log

Agonist Capacity of NM and Its Antagonism by MRSAL in the GPI.
concentration and y

(e) 110.2 nM, 38.9 (r
in presence of MRSAL,
in presence of MRSAL,
in presence of MRSAL,

= response,

the calculated

rc 5o

and slope

(~)

= 0.62, N = 300)
8.5 ~M (•) 163.3 nM, 54.2 (r = 0.93, N = 30)
21.2 ~ (•) 377.1 nM, 42.9 (r = 0.86, N =50)
85.0 ~ (T) 2,844.5 nM, 34.7 (r = 0.96, N = 55)

Clear points (o, o, v) were not used in linear regression.

values are:
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Figure 13.
When x

= log

Agonist Capacity of NM and Its Antagonism by HRSAL in the MVD.
concentration and y

= response,

the calculated

1c50

and slope (Q) values are:

NM (e ) 132.3 nM, 55.2 (r = 0.82, N = 112)
NM in presence of MRSAL, 42.5 J.LM (.a.) 305.8 nH, 61.0 (r = 0.93, N = 28)
Clear point

(~)

was not used in linear regression.
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Figure 14.
When x

= log

DHM
DHM
DHM
DHM

Agonist Capacity of DHM and Its Antagonism by MRSAL in the GPI.
concentration and y

= response,

the calculated

rc 50 and slope

(~)

(•) 45.1 nM, 35.8 (r = 0.72, N = 128)
in presence of MRSAL, 85 ~M (•) 67.0 nM, 31.2 (r = 0.84, N = 35)
in presence of HRSAL, 21.2 JA-M (A) 144.2 nM, 41.1 (r = 0.79, N = 43)
in presence of MRSAL, 85.0 p.H ('") 6,478 .. 9 nM, 20.4 (r = 0.86, N = 65)

Clear points (o, o, 6) were not used in linear regression.

values are:
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Figure 15.
When x

= log

Agonist Capacity of DHM and Its Antagonism by MRSAL in the MVD.
concentration and y

= response,

the calculated IC 50 and slope

DHM (e) 82.7 nM, 37.5 (r = 0.72, N = 30)
DHM in presence of MRSAL, 42.5 ~M (A) 346.1 nM, 42.0 (r
Clear point (o) was not used in linear regression.

= 0.88,

N

(~)

= 39)

values are:
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Figure 16.
When x

= log

Agonist Capacity of EKC and Its Antagonism by MRSAL in the GPI.
concentration and y

= response,

the calculated

rc 50 and slope

EKC (e) 1.3 nM, 35.5 (r = 0.76, N = 135)
EKC in presence of MRSAL, 21.2~M (•) 2.7 nM, 41.2 (r = 0.82, N =56)
EKC in presence of MRSAL, 85.0 ~M (T) 19.3 nM, 21.8 (r = 0.90, N =55)
Clear points (o, .o, v) were not used in linear regression.

lQ) values are:
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Figure 17.
When x

= log

Agonist Capacity of EKC and Its Antagonism by MRSAL in the MVD.
concentration and y

= response,

the calculated IC 5 o and slope

EKC (e) 7.7 nM, 55.8 (r = 0.92, N = 37)
EKC in presence of MRSAL, 85p.H (.&) 17.4 nM, 53.3 (r = 0.93, N = 30)
Clear point (o) was not used in linear regression.
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Figure 18.
When x

= log

Agonist Capacity of U-50,488H and Its Antagonism by MRSAL in the GPI.
concentration and y

= response,

the calculated

rc5o

U-50,488H (e) 6.4 nM, 27.4 (r = 0.67, N = 116)
U-50,488H in presence of MRSAL, 21.2~M (•) 12.4 nM, 41.1 (r
U-50,488H in presence of MRSAL, 85.0 ~M (T) 50.3 nM, 29.8 (r
Clear points (o, v) were not used in linear regression.

and slope

= 0.91,
= 0.94,

(~)

values are:

N = 70)
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Figure 19.
When x

= log

Agonist Capacity of U-50,488H and Its Antagonism by MRSAL jn the MVD.
concentration and y

= response,

the calculated

U-50,488H ( • ) 24.4 nM, 28.9 (r = 0.85, N = 57)
U-50,488H in presence of MRSAL, 85.0 pM (£) 162.9
Clear point

(~)

was not used in linear regression.

~f,

Ic 50

and slope

41.1 (r

= 0.82,

(~)
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Figure 20.
When x

= log

Agonist Capacity of BH-END and Its Antagonism by MRSAL in the GPI.
concentration and y

= response, the
= 0.92, N = 60)

calculated

rc 50

and slope

(~)

BH-END (e) 37.0 nM, 48.5 (r
BwEND in presence of MRSAL, 21.2 JJ-M (A) 228:.3 nM, 34.5 (r = 0.87, N = 28)
BH-END in presence of MRSAL, 42.5 Jill (T) 366.4 nM, 34.4 (r = 0.92, N = 57)
Clear points (6, v) were not used in linear regression.
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Figure 21.

Agonist Capacity of BwEND and Its Antagonism by MRSAL in the MVD.

When x = log concentration and y = response, the calculated

rc 50

and slope

(£0 values are:

BH-END (e) 48.4 nM, 35.8 (r = 0.94, N = 54)
BH-END in presence of MRSAL, 42.5p,H (A) 76.4 nM, 34.6 (r = 0.91, N = 30)
BH-END in presence of MRSAL, 85.0 p)1 (•) 77.3 nM, 43.8 (r = 0.96, N = 42)
Clear point (o) was not used in linear regression.

93

1/)

cO

cc

N

p."')

""""

~

"'r...:

1/)

c::
._..
c::

·Q

......,)

~

cc

'......,)

N

Q,)

cO

c::
u

c::

Q

~
~

u

c::

·Q

......,)

~

,...
Ll"l

(~) SUO!l:H~..JlUOJ

paletnWnS

Alle:lJ..Jl:lat3 JO uon~Q~4UI

.c
~

u

c::

Figure 22.

Agonist Capacity of DYN 1-13 and Its Antagonism by MRSAL in the GPI.

When x = log concentration and y = response, the calculated rc 50 and slope

{~)

values are:

DYN 1-13 (e) 1.8 nM, 44.4 (r = 0.86, N = 196)
DYN 1-13 in presence of MRSAL, 21.2~M (•) 3.6 nM, 46.1 (r = 0.91, N = 70)
DYN 1-13 in presence of MRSAL, a85.0~M (T) 14.5 nM, 41.8 (r = 0.80, N = 62)
Clear points (o,

£:..,

v)

were not used in linear regression.
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Figure 23.
When x

= log

Agonist Capacity of DYN 1- 13 and Its Antagonism by MRSAL in the MVD.
concentration and y

= response,

the calculated

rc 50 and slope (Q) values are:

DYN 1-13 (e) 8.2 nM, 29.9 (r = 0.10, N = 70)
DYN 1- 13 in presence of MRSAL, 42.5 J.l'H (•) 17.5 nH, 31.2 (r = 0.78, N = 24)
DYN 1- 13 in presence of MRSAL, 85.0 JlH (•) 63.4 nM, 31.9 (r = 0.93, N = 36)
Clear points

(~,

o) were not used in linear regression.
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Figure 24.

Agonist Capacity of Leu-ENK and Its Antagonism by MRSAL in the GPI.

When x = log concentration and y = response, the calculated
Leu-ENK
Leu-ENK
Leu-ENK
Leu-ENK

(e) 408.0 nM, 43.6 (r
in presence of MRSAL,
in presence of MRSAL,
in presence of MRSAL,

Clear points ( o,

r:, ,

rc 50 and slope

lQ) values are:

= 0.86, N = 8~)
4.2p..M (•) 1, l.f49.6 nH, 49.8 (r = 0.85, N = 21)
21.2 }Jl'f (.&.) 10,937.0 nM, 27.2 (r = 0.92, N = 70)
170.0 ~M (T) 158,489.3 nM, 17.5 (r = 0.89, N = 49)

v ) were not used in linear progression.
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Figure 25.
When x

= log

Agonist Capacity of Leu-ENK and Its Antagonism by HRSAL in the WID.
concentration and y

= response,

the calculated

rc 5 o

and slope

(~)

values are:

Leu-ENK (e) 19.6 nM, 42.9 ( r = 0.91, N = 63)
Leu-ENK in presence of MRSAL, 42.5 ~H (•) 23.6 n}f, 37.9 (r = 0.87, N = 24)
Leu-ENK in presence of MRSAL, 170.0 ~M (•) 50.1 ru1, 39.2 ( r = 0.96, N = 36)

101

0

0

a:>

~
0

"'

I:
c::

~

loC
,....,

""""c::

·Q

.-I
~

'.-I
c::
0

aO

ct)

u

c::
Q

u

c::

~

"'

·Q

.-I
~

.c
:I
u
c::

It:!
,....,

(")

SUOJ1:U~.J1UOJ

A((£:>~.Jl=>at3

palB(nW!lS

JO uon lQ!4UI

Figure 26.

Agonist Capacity of DADLE and Its Antagonism by MRSAL in the GPI.

When x = log concentration and y = response, the calculated

rc 50

and slope

(~)

DADLE (•) 19.9 nM, 35.7 (r = 0.93, N = 80)
DADLE in presence of MRSAL, 21, 2 ~ (•) 101.7 nM, 36.4 (r = 0.94, N = 35)
DADLE in presence of MRSAL, 85.0 ~ (T) 210.2 nM, 40.9 (r = 0.96, N = 56)
Clear points ( o,

6

,

v ) were not used in linear regression.

values are:
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Figure 27.
When x

= log

Agonist Capacity of DADLE and Its Antagonism by MRSAL in the MVD.
concentration and y

= response,

the calculated

rc 50 and slope (Q) values are:

DADLE ( • ) 0.1 nM, 60.5 (r = 0.92, N = 48)
DADLE in presence of MRSAL, 170.0 ~M (•) 0.5 nM, 51.5 (r = 0.94, N =57)
Clear point (o) was not used in linear regression.
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against Leu-ENK and BH-END (Figures 20 and 24).

The IC 5 o value for

Leu-ENK was increased from 408.0 to 1,449.6 nM in the presence of MRSAL
(4.2

~M).

This concentration of MRSAL

(4.2~M)

concentration used for an effective antagonism.

was the lowest
The IC 5 o value for

BH-END increased from 37.0 to 228.3 nM in the presence of MRSAL
(21.2 pM).

In addition, in both cases there was a significant loss of

parallelism with higher concentrations of MRSAL.

Slope

(~)

values

decreased from 43.6 to 27.2 for Leu-ENK in the presence of MRSAL at
concentrations of 21.2

~(Figure

24), and from 48.5 to 34.5 for BH-END

under the same conditions (Figure 20).
In the MVD, the most effective antagonism with MRSAL was against
DHM and NM (Figures 13 and 15).
B~END

In contrast, the effects of Leu-ENK and

were resistant to MRSAL antagonism (Figures 21 and 25).

There-

for-e, it was necessary to use MRSAL in concentrations as high as

170f~M

in order to obtain some displacement of the concentration-response curve
of Leu-ENK to the right.

The Ic 50 values of Leu-ENK increased slightly

from 19.6 to 39.2 nM (Figure 25).

In addition, as shown in Figure 21,

the IC 50 value for BH-END only increased from 48.4 to 77.3 nM in the
presence of MRSAL (85

~).

MRSAL was also effective against compound J in both preparations.
In this case, the antagonism was also reversible and concentration
dependent (Figures 9 and 10).
Figures 28 to 43 illustrate the antagonism of MRSAL when this
compound was added after the agonists.

MRSAL was able to antagonize the

decrease in muscular contractions induced by all the opioid agonists
tested.

The recovery of muscular contractions was concentration-

dependent and very fast (30 sec) after MRSAL was added to the bath.
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Agonist Activity of EKC and Its Antagonism by MRSAL in the GPI.
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wash.

Muscular contractions were recorded 40 min arter

0

"'

11 min I

•
t

EKC
10.1 nM

Figure 31.
W x 2:

M~~SAL
W X 2
8~) ~M ( 10 min)

Agonist Activity of EKC and Its Antatgonism by MRSAL in the MVD.
The preparation was washed 2 times.
after wash.

Muscular contractions were recorded 10 min
0

•

I •

llliii/iJ

en

..

0

t0

f, min~

t

U-50, 488H
8.6 nM

Figure 32.
W x 8:

Agonist Activity or

U-50,~88H and

'

~uuu~w~~~

t

MRSAL
170 .JJM

t

W X 8
(60 min)

Its Antagonism by MRSAL in the GPI.

after
wash.
The preparation
was washed 8 times.

Muscular contractions were recorded 60 min
__.
__.
__.

0)

~

'II

0

t

t t

U-50. 488 H MRSAl MRSAL
42.8 nN
85 uM 170 uM

Figure 33.
W x 2:

t

llUWWUlUUWUUWUUlJ

WX2
(10 min)

II min I

Agonist Activity or U-50,488H and Its Antagonism by HRSAL in the MVD.
The preparation
was washed 2 times.
after
wash.

Muscular contractions were recorded 10 min

_.
1\)

----------------------0')

1/)

1/lll!llll!!llll!ll,
I

;

I,,

f'0

1111111

~ min~

t

J

rs. g 11M

tMRSAL t
MRSAL

21.2 11M

WJ!illill

42.511M

UlU,

t
WX3
( 15 min)

Figure 34.

W x 3:

Agoniot Activity or J and Ita Antagoniom by MRsAL in the GPI.
after Wash.

The Preparation waa waahed 3 timea.

Muaoular contractions were recorded 15 min

_.
_.
w

IIii Ill Ili" Ill IIIII Idil. Iill/ I~~ illr
0"1

•

111111111111111111 IIIII I

II Ill II II II II II Ill I I I I IIIII I I II I I I 111111 I I I

11111111111111111111111111111111111111

~

0

.

llllllllllllllllllllllllllllllllllllllllllllllllllllllllllll.llllllllllllllllllllllllllllllllllllllll

t
J
15 .9

Figure 35.
W x 2:

~M

t t

·-~

t

MRSAL MRSAL W X 2
42.5 JJM 85 ~M ( 10 min)

1,

min

I

Agonist Activity of J and Its Antagonism by MRSAL in the MVD.
The preparation was washed 2 times.
after wash.

Muscular contractions were recorded 10 min
.l::"

0'1
lf)

.

t0

t

J1 mtn I

BH-END
57.7 nM

Figure 36.

W x 1:

Agonist Activity

or

t

MRSAL
85 JJM

t

WX l
(1 min)

Ba-END and Its Antagonism by MRSAL in the GPI.

arter
Wash.
The Preparation
was washed 1 time.

Muscular contractions were recorded within 1 min

Ul

---

I,

.· 'H; ·'· ·'
'II

0'>

l.f)
f'f)

0

1,

min

I

l i l l lh il l l il l l l l l l l l l l l l l l/ {/ l/ {/ l/l l l/( / 1/l l / 1/l l/fl~

t t

BH- END MRSAL
57 .7nM 85JJM

Figure 37.
W x 1:

t
WX 1
( 1 min)

Agonist Ac tivity of BH- END and Its Antagoni s m by MRSAL in the lWD.
The preparation
was was hed 1 time.
after
was h.

Muscular contrac tions were recorded within 1 min
0\

lliliii!JIII!I!il

· ltilllfllllll!!llllllllllllj~

C")

co
t0
I

JJJJJJJJJJill}
~, mtn f

Figure 38.

W x 1:

t

DYN 1-13
1.2 nM

t

MRSAL
85 JJM

JJJJJJJJWJJJJJJJJJllilliWU\

t

WX I
( 1 min)

Agonist Activity or DYN 1-13 and Its Antagonism by HRSAL in the GPI.
The preparation
was washed 1 time.
arter
wash.

Muscular contractions were recorded within 1 min

~
~

~

I .1,

en'

l.(.)

11111111111111 IIfIIIll f11111111

t0.
0

1-1
I,

Figure 39.

Wx 2:

min

1

t t

t.

DYN 1- 13 MRSAL
WX2
3.0 nM 85 JJM ( 10 min)

Agonist Activity of DYN 1- 13 and Its1 Antagonism by HRSAL in the HVD • .
The preparation was washed 2 times.
after wash.

Huscular contractions were recorded 10 min
_.
CX>

en

.

lf)

t0

I I min I

t
leu-ENK
360 nM

Figure 40.
W x 2:

t

MRSAL
85 JJM

t

WX2
( 10 min)

Agonist Activity or Leu-ENK and Its AntagOnism by HRSAL in the GPI.
The preparation
was washed 2 times.
after
wash.

Muscular contractions were recorded 10 min

\.0

-

£1

I

if({ f!fllfIll/IIIII/lfllflli

.. ,,Jillllllllllllllllllllllllll//

IIfl tl!lt lt l ~

ltttttt

~~~-Iilli
Leu-ENK MRSAL
36 nM
170 M
J1

Figure 41.

W x 2:

t

WX2

(10 rnin)

I

I
I

min

Agonist Activity of Leu- ENK and Its Antagonism by MRSAL in the MVD.

The preparation
was washed 2 times.
after
wash.

Muscular contractions were recorded 10 min
1\}

0

~I

0'>
L[)

t0

.

,!//llll/flllfll/!ll!lll/1!////h

--n

.illllllllllill.
.
.
.
.
.
tii~~rJWJJJJJJlillfu\llil
JrJJ~uu
· · : !

. ' , •
.I .•
'O
.t .. ...

1

J .I ; .I • '

II min I

~

'

• '

..

I :

l

~2.

W x 2:

I

~

tDADLE MRSAL
t

35 .1 nM

Figure

·I

85 JJM

:~
.• l .

· uw~ ~
i\ :

1 ::.

•1

1

t

! 'I

t

MRSAL

WX2

170 JJM

(10 min)

Agonist Activity of DADLE and Its Antagonism by MRSAL in the GPI.

The preparation
was washed 2 times,
after
wash.

Muscular contractions were recorded 10 min
-"

1\.>
-"

0

IUWUIOMw

t,

Figure 43.
W x 2:

min I

t

~

II

t

IIIII

t

DADLE

MRSAL

W X 2

0.18 nM

170 JJM

( 10 min)

Agonist Activity of DADLE and Its Antagonism by MRSAL in the MVD.
The preparation
was washed 2 times.
after
wash.

Muscular contractions were recorded 10 min
N
N

123
Qualitatively, the ability of MRSAL to antagonize the effects of
the opioids varied among some agonists.

NM

(~

prototype) was better

antagonized in the GPI (Figure 28) than EKC and U-50,488H (Figures 30
and 32).

DHM had similar characteristics as NM (not shown).

In

addition, EKC (kappa prototype) was better antagonized by MRSAL
(Figure 30) than U-50,488H, another kappa agonist (Figure 32).
quality of antagonism also differs from GPI to MVD.
concentrations of MRSAL (42.5-170.0
agonists.

~M)

The

In general, higher

were used in the MVD for most

DHM (Figure 29) and NM (not shown) had similar behaviors

while EKC (Figure 31) was again better antagonized by MRSAL (85

~M)

than

U-50,488H (Figure 33).
Compound J (Figures 34 and 35) demonstrated more similarities of
action

to~

prototypes (NM, DHM) than to kappa agonists (EKC and

U-50,488H) in both preparations.
The recovery of muscle contraction inhibition induced by the
peptide agonists (BH-END, DYN 1-13, Leu-ENK and DADLE) in the presence
of MRSAL in both preparations is shown in Figures 36 to 43.

In the GPI,

BH-END (Figure 36) was better antagonized by MRSAL than in the MVD
(Figure 37) while DYN 1-13 was equally sensitive to MRSAL antagonism
(Figures 38 and 39).

In contrast, Leu-ENK and DADLE were far better

antagonized in the GPI (Figures 40 and 42) than in the MVD (Figures 41
and 43).

In the latter case, the recovery rate was slower and required

higher concentrations of MRSAL (170flM) for antagonism.

This subject

will be better discussed in a subsequent section titled "Recovery Rate
for the Peptides in Guinea Pig Ileum Longitudinal Muscle."
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Antagonist- Receptor Affinity of
NX. pA~ Values
The opioid receptor affinity of the prototype antagonist, NX, was
established by calculating its pA2 value against several opioid agonist
prototypes and compound J.

The calculated pA2 values for NX antagonism

of opioid agonists in the GPI and MVD are shown in Table XII.

In both

preparations, NX demonstrated its highest affinity for mu receptors (NM
and DHM) while its lowest affinity was observed for kappa (EKC,
U- 50,488H, DYN 1- 13) and delta (Leu-ENK and DADLE) receptors.

The

receptor preference for BH- END will be fully discussed later .
Compound J was antagonized by NX in the same manner as NM, DHM and
Leu- ENK in the GPI.

There was no significant difference between the pA2

values of J, DHM, BH- END and Leu- ENK.
significant difference (£

However, there was a small but

< 0.05) between the pA 2 values for NX

antagonism of J, NM and DADLE.

In the same preparation, the pA2 value

for NX antagonism of J was very highly significantly different (k

<

0.001) from that of kappa receptors prototypes like EKC, U- 50,488H and
DYN 1-13 (Table XII).
In the MVD, the pA2 value for NX antagonism of J was slightly lower
(8.00) than in the GPI (8.17).
highly significant difference

In this preparation, there was a very
(~

< 0.001) between the pA 2 values of

J and

DHM, EKC, DYN 1- 13, BH- END, Leu- ENK and DADLE, but not NM (Table XII).
The apparent equilibrium dissociation constant (Ke) of NX for
several opioid agonists in the GPI and MVD as reported by other
investigators is presented in Tables XIII, XIV and XV.

This constant

(Ke) measures the effectiveness of an antagonist against a given agonist
and represents the concentration of the antagonist which is necessary to
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Table XII.

Calculated pA2 Values for NX Antagonism of Several Opioid
Agonists.

MVD

GPI

Opioid
Agonist

N

pA2

±

S.E.

N

pA2

±

Nl1

15

8.40

±

o. 06*

5

8.12

±

0.05

DHM

8

8.27

±

0.02

11

8.48

±

0. 08***

EKC

14

7.62

±

0.08 ***

9

7.15

±

0.07 ***

U- 50,488H

13

7.53

±

0.09***

10

7.72

±

0 .07*

7

7 . 87

±

0.13

13

7.52

±

0. 07 ***

DYN 1- 13

10

7.44

±

0.05 ***

13

7.48

±

o.og • u

Leu- ENK

7

8.32

±

0.06

21

7.41

±

0.06 *U

DADLE

7

7.80 ± 0. 06 *

BH- END

J

30

8.17

±

Level of significance relative to J:

7.03 ± 0.09 ***

7

8. 00

20

0.07

*

E < 0.05,

s.E.

***

±

E < 0.001.

0.08
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Table XIII.

Apparent

~uilibritml

Di.ssoci.ation Constant (Ke) of NX in the GPI as Re{X)rte:::l

by Other Investigators.

~ioid

Agonist

DIM
EKC

Ke (rt.f) 1

pA22
value

2.64 ± 0.04

8.58

Waterfield et al., 1977

2.64 ± 0.04

8.58

Lord et .§l.. , 1977

3.5 (2.5-4.7)

8.46

Huidobro-'Ibro et al., 1982

3.5 ± 0.5

8.46

Chavkin et al. , 1982

8.46 ± 0.223

Hui.dobro-Toro et al., 1981b

3.5 (2.5-4.7)

8.46

YoshimJra et al., 1982c

1.9 ± 0.2

8.72

H..ltch:i.nson et al., 1975

1.9

8.72

Paterson et al., 1984

2.8 ± 0.2

8.55

Leslie et al., 1980

14.9 ± 0. 9

7.83

Lord et al., 1977

21.9 (15.6-30.6)

7.66

Huidobro-'Ibro et al. , 1982

13.0 ± 1.53

7.89

Cl<a et al., 1982

23.0 ± 3.7

7.64

Chavkin et al., 1982

23.8 (17.1- 33.1)

7.62

Yosh:il!lura. et al., 1982c

7.88 ± 0.1o3

Taken:ori an:l. Portoghese, 1984

7.66

Yoshimura et al., 1982a

21.9 (15.63-30.62)

7.88 ±

U-50,l!88H

Refereooe

o.og3

Takem:>ri et al., 1981

14.9 ± 0.9

7.83

Hutchinson et al., 1975

15.0

7.82

Paterson et al. , 1984

_4

1Ke value reporte:::l either as Mean ± S.E. or with its 95% confideooe limits.
2pA2 value was calculated fran the expression pA2 = - log Ke (in nolar units).
3pA2 value re{X)rte:::l by the investigators as M3an ± s. E.
4Not re{X)rte:::l in the scientific literature.
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Table XIV.

Apparent Equilibrium Dissociation Constant ( Ke) of NX in the GPI as Reported
by Other Investigators.

~ioid

pAl

Agonist

Ke (rt1) 1

value

Refereme

B-END

2.86 ± 0.42

8.54

Loro et a1.. , 1977

27.0 (19.5-37.4)

7.57

Huidobro-'Ibro et al., 1982

18.8 ± 2.49

7.73

Cl<:a et a1.. , 1982

21.0 ± 1.70

7.68

Chavkin et al., 1982

22.4 (16.98-29.51)

7.65

27.0 (19.5-37.4)

7.57

25.0

7.60

Paterson et al., 1984

2.43 ± 0.67

8.61

Waterfield et al., 1977

2.43 ± 0.67

8.61

4.8 (3.3-6.9)

8.32

Huidobro-'Ibro et al. , 1982

4.4 ± 0.8

8.36

Chavkin et al., 1982

4.8 (3.33-6.89)

8.32

5.0 (3.7-6.9)

8.30

2.4

8.62

Paterson et al. , 1984

8.51 ± 0.123

'l'akem:lri arrl Portoghese, 1985b

8.59

Leslie et al., 1980

DYN 1- 13

Leu-ENK

DADLE

2.6 ± 0.1

1Ke value reported either as ~ ± S.E. or with its 95% confideooe limits.
2PA2 value was calculated fran the expression pA
2 -log Ke (in nolar units).
3pA2 value reported by the .investigatol"S as Mean ± S.E.

=
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Table X:V,

Opioid
Agonist

Apparent Fquilibriun Dissociation Constant (Ke) of NX in the MVD as
Rep:>rtOO by Other Investigators.

pA22
Ke ( rt-1) 1

value

1.84 ± 0.20

8.74

Waterfield et al., W77

1.84 ± 0.20

8.74

Lord et al., 19TI

1.20

8.92

Schulz et al., 1984

3.1 ± 0.3

8.51

Hutchinson et al,, 1975

3.1

8.51

Paterson et al,, 1984

DIM

2.6 ± 0.2

8.59

Leslie et al,, 1980

FXC

11.0 ± 0.6

7.~

Lord et al., 19TI

15.2 ± 1.7

7.82

Cka et .sl.. ,

11.0 ± 0.6

7.~

Hutchinson et al,, 1975

15.2 ± 1.7

7.82

Kajiwara et al., 1986

11.0

7.~

Paterson et al,, 1984

U-50,488H

Reference

1982

_4

BfrEND

21.7 ± 1.2

7.66

Lord et al,, 19TI

DYN 1- 13

36.5 ± 4.7

7.44

Cka et al,,

30.5

7.52

Schulz et al., 1984

16.0

7.80

Paterson et al,, 1984

21.4 ± 3.3

7.67

Waterfield et al,, 19TI

21.4 ± 3.3

7.67

Lord et al., 19TI

21.0

7.68

Paterson et al. , 1984

27.6

7.56

Sclrulz et al,,

7.39 ± 0.213

Takarori an:l Port:.q9:lese, 1984

25.6 ± 2.4

7.59

Kajiwara et al. , 1986

27.3 ± 4.8

7.56

Leslie et al., 1980

Leu-ENK

DADLE

1982

1984

1Ke value rep:>rtOO as t-Ean ± s.E.
2pA2 value was calcul.atErl fran the expression pA2 = -log Ke (in nolar units).
3pA2 value rep:>rtOO by the investigators as M3an ± s. E.

4Not rep:>rted in the scientific literature,
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double the concentration of the agonist to give the same pharmacological
effect obtained in the absence of the antagonist (Lord, et al., 1977).
The effectiveness of an antagonist against an agonist may also be
expressed as pA2 value which is the negative logarithm of Ke.
Therefore, the pA 2 value was calculated from the expression pA2

= log

Ke

(in molar units) and it is also presented (Tables XIII, XIV and XV) in
addition to the Ke values.
In general, the pA2 values obtained in this study agree with those
reported in the literature (Tables XII, XIII, XIV and XV).

However, in

the GPI, the pA2 values for NX antagonism of BH-END and DADLE found in
this research were lower (7.87 and 7.80) than those reported (Table XIV).
A similar situation was observed in the MVD where pA2 values for NX
antagonism of NM, EKC and DADLE were lower (8.12, 7.15 and 7.03,
respectively) than those previously reported by others (Table XV).
Antagonist-Receptor Affinity of
MRSAL, pA~ Values
The opioid receptor affinity for compound MRSAL was assessed by
calculating its pA2 value against several opioid prototypes and compound J
(Table XVI).

In the GPI, MRSAL demonstrated greater affinity for Leu-ENK

and DADLE receptors, the mu receptor (NM, DHM), BH-END and compound J
receptors.

Although MRSAL showed less affinity for the kappa sites when

assessed using EKC and U-50,488H as prototypes selective for this
receptor, its pA2 value against the DYN-13 opioid receptor was much
higher (5.10) than those against EKC (4.50) and U-50,488H (4.77) and
comparable to

~

prototypes.

In the MVD (Table XVI), the highest affinity was observed toward
the

~-receptor

(NM, DHM) and compound J.

Lower pA2 values were
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Table XVI.

Opioid
Agonist

Calculated pA2 Values for MRSAL Antagonism of Several
Opioid Agonists.

GPI
N

pA2 ± S.E.

N

MVD
pA2

±

s.E.

NM

28

5.1!1 ± 0. 02

17

5.10 ± 0.07

DHM

21

5.53 ± 0.05

12

5.22 ± 0.13

EKC

25

1!.50 ± 0.07

12

1!.35 ± 0.12

U-50,1!88H

22

lj. 77 ±

0.07

12

1!.90 ± 0.07

BH-END

17

5.23 ± 0.03

15

4.50 ± 0.06

DYN 1-13

21!

5.10 ± 0.05

20

lj. 98 ±

Leu-ENK

20

5.71 ± 0.05

12

4.05 ± 0.08

DADLE

20

5.22 ± 0.03

12

lj. 11 ±

J

20

5.09 ± o.ol!

18

5.12 ± 0.08

0.09

0. 11
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obtained for MRSAL antagonism of U- 50,488H,

B~END,

EKC and DYN 1- 13 .

A

much lower capacity of antagonism was observed against DADLE and Leu- ENK
in this preparation, but not in the GPI.
Antagonist Potency. Ke Values for
NX and MRSAL in the GPI and MYD
The opioid antagonist'potency of NX and MRSAL against several
opioid agonists is shown in Table XVII .

In the GPI, there was close

agreement between the Ke values found in this study and those reported
by other investigators (Tables XIII and XIV).
with the Ke value for NX against BH- END.

One exception was seen

We found a slight decrease in

potency for NX antagonism against this peptide (Ke

= 17.8

nM)

as

compared to that of 2.86 nM reported by Lord et al. (1977) (Table XIV).
NX was more potent in antagonizing the effects of NM, Leu- ENK, DHM and J
than DADLE and

B&- E~ID.

A decrease of antagonist potency was further

observed when NX was tested against EKC, U-50,488H and DYN 1- 13.
In the MVD, highest antagonist potency for NX was seen against DHM,
NM and J.

NX demonstrated a wide range of antagonist potency when

tested against U-50,488H, BH- END 1 DYN 1- 13, Leu- ENK and EKC (Table XVII).
This antagonist was more potent against U- 50,488H than against DYN 1- 13
or EKC, but demonstrated similar antagonist potency against
DYN 1- 13 and Leu- ENK.

B~END,

The lowest antagonist potency of NX was seen

against DADLE with a Ke value of 103.5 nM (Table XVII ).

In this study,

the Ke values for NX antagonism in the MVD against NM and Leu- ENK were
higher than those reported by others.

In addition, even higher values

were obtained when NX was tested against EKC and DADLE (Tables XV, XVII).
I n contrast to NX, MRSAL demonstrated its highest antagonist
potency against Leu- ENK, DHM and NM in the GPI and DHM, NM and J in the
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Table XVII.

Antagonist Potercy, Ke Values1 for NX an:i MRSAL ilgajnst Several ~ioid
.Agonists.

Agonist

MVI)2

GPI2

~ioid

N

NX (111)

N

MRSAL ~M)

N

NX (111)

N

MRSAL ~)

tl1

15

4.5 ± 0.5

28

4.0 ± 0.2

15

8.3 ± 0.9

17

9.6 ± 1.5

Dll1

8

5.5 ± 0.3

21

3.5 ± 0.6

11

4.0 ± 0.8

12

9.1 ± 2.5

EKC

14

30.2 ± 6.8

25

42.6 ± 7.1

9

78.5 ± 12.7

12

13.0 ± 1.9

'(}-50,488H 13

37.0 ± 6.9

22

23.7 ± 4.8

10

21.4 ± 4.4

12

13.0 ± 1.9

Bfr-END

7

17.8 ± 5.4

17

6.1 ± 0.4

13

35.1 ± 5.3

15

37.4 ± 5.8

10

39.8 ± 7.0

24

8.9 ± 0.9

13

42.4 ± 8.1

20

15.0 ± 2.9

~ENK

7

5.0 ± 0.5

20

2.2 ± 0.2

21

46.2 ± 6.1

12

104.9 ± 15.7

DADLE

7

17.0 ± 2.2

20

6.4 ± 0.5

7

103.5 ± 17.8

12

128.6 ±57 .5

30

9.4 ± 1.3

20

9.0 ± 0.1

20

13.8 ± 2.4

18

10.5 ± 3.0

1Ke value was calcul.ate:i fran the expression pA2

= -1~

DYN 1- 13

J

2vaJ..ues are exp!"'eS.SEd as M3an ±

s.E.

Ke (in molar units).

133
MVD (Table XVII).
antagonism (2.2

~M)

Leu- ENK was particularly more sens i tive to MRSAL
in the GPI than any other agonist tested.

Inter-

mediate antagonist potency of MRSAL was seen against the agonists
BH-END, DADLE, DYN 1- 13 and J in the GPI and EKC, U- 50,488H and DYN 1- 13
in the MVD.
antagonist
GPI.

Among these agonists, DYN 1- 13 was more sensitive to this
(8.9~M)

than U- 50,488H (23.7

~M)

and EKC (42 . 6

~M)

in the

In contrast to the GPI, a decrease in antagonist potency was

further observed in the MVD when MRSAL was tested against BH- END,
Leu- ENK and DADLE.

In the latter preparation, MRSAL displayed very low

potency of antagonism against Leu- ENK

(104.9~M)

and DADLE (128.6

~M)

(Table XVII).
In both preparations, J was more sensitive to NX and MRSAL
antagonism than kappa and delta prototypes.
Recovery Rate of Muscular Contraction
for the Peptides in the GPI
The recovery rates for muscular contraction for BH- END, DYN 1-13
and Leu- ENK were calculated in the absence and presence of the
antagonist MRSAL in the GPI (Tables XVIII, XIX, XX).

The spontaneous

recovery of inhibition at 5 min in the absence of MRSAL was slowest for
BH- END (13%, Table XVIII), intermediate for DYN 1- 13 (36%, Table XIX)
and fastest for Leu- ENK (66%, Table XX).
In general, there was a significant

difference(~<

0.001) in the

recovery rate of these peptides in the presence of MRSAL as compared to
control at the same time interval .
increased the recovery rate for

MRSAL (4.2 -

B~END

84.0~M),

significantly

(Table XVIII), DYN 1- 13 (Table

XIX ) and Leu- ENK (Table XX) at 5, 10 and 15 min.

However, there was no

significant difference in the recovery rate for DYN- 13 in the presence
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Table XVlli.

Recovery Rate of M..lscular Contractions for
Presence of MRSAL on GPI.

~END

in the Absence ani

Recovery Rate (%) 1

MRSAL

Vili)

N

0

4

4.2
42.5

5 min

10 min

15 min

20 min

13.2 ± 2.3

49.5 ± 1.9

71.6 ± 2.2

93.4 ± 1.2

4

89.2 ± 2.6*

98.5 ± 1.5*

7

94.3 ± 2.6*

1Results are expressa:i as M3an ± S.E.
*S:ign:i.ficantJ.y dif'ferent fran control at the sama tine interval,

.f.< 0.001.
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Table

xn::.

MRSAL
(}l.M)
0

Recovery Rate of M..tscular Contractions for DYN 1-13 in the .Abseme an:l
Presence of MRSAL in the GPI.

Recovery Rate (%) 1

N

5 min

10 min

15 min

20

36.0 ± 2.5

77.7 ± 3.4

96.2 ± 1.7

0.2

7

34.6 ± 4.5

80.0 ± 3.0

97.6 ± 2.4

0.8

4

36.0 ± 2.1

72.8 ± 2.0

90.8 ± 2.3

8.5

4

45.8 ± 1.6

80.9 ± 2.0

101.2 ± 1.2

21.2

8

64.4 ± 3.5*

99.8 ± 2.0*

120.0 ± 5.3*

42.5

6

85.2 ± 1.5*

1exi.8 ± 1.2*

85 .0

10

107.6 ± 4.4*

1ResuJ.ts are expressed as~± S.E.

*Significantly different fran control at the sane tine interval, _t < 0.001.

20 min

98.2 ± 2.8
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Table XX.

Recovery Rate of Muscular Contractions for Leu- ENK in the
Absence and Presence of MRSAL in the GPI

Recovery Rate (%) 1

MRSAL
(~M)

0

N
11

5 min
66.0 ± 1.9

21.2

7

92.6 ± 1.9*

85.0

3

109.2 ± 0.3 *

1Results are expressed as Mean ± S.E.
*Significantly dif ferent from contr ol at the same time interval, P

< 0 . 001.
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of MRSAL in concentrations from 0.2 to 8.5

~M

at the same time intervals

(Table XIX) .
Acute Tolerance Induced
by DYN 1- 13 in the GPI
DYN 1- 13 produced acute tolerance in the GPI when using both the
"single-dose" (Fig. 44) and the "cumulative" (Fig. 45) methods of
documenting a dose- response curve and also when the same concentration
of the peptide was repeated during 130 min (Table XXI).

However, this

effect seemed more pronounced when DYN 1-13 was tested using the
"single-dose" method with a 25 min interval between doses (Fig. 44).
There was a higher level of significance (E

< 0.001) between the first

and second concentration-effect curves when using the "single-dose" than
when the "cumulative" dose-response method (Fig. 45) was used.

When the

same concentration of DYN 1- 13 was repeated duri ng 130 min at 30- 40 min
intervals, the effect of acute tolerance induced by this peptide >;as
apparent statistically at 30 min (Table XXI).
BH- END, Leu- ENK and DADLE did not induce acute tolerance in the
GPI.

Concentration-response curves for these peptides were reproducible

for a period up to 5 h and even after antagonism experiments with
MRSAL.

This further demonstrates that MRSAL can be "washed out" well

from the preparation.
Although it seemed that the spontaneous recovery rate for DYN 1- 13
increased with the development of tolerance, there was no significant
difference between the recovery rates of muscular contraction at 0 min
and 120 min later in the same preparation (not shown).

Figure 44.

Acute Tolerance Effect Induced by DYN 1-13 on the GPI When Using "Single-Dose" Method.

Circles (o) correspond to the first DYN 1-13 concentration-effect curve, while squares (o)
represent the second DYN 1-13 concentration-effect curve as described in Methods.
Significance level:

~

< 0.01

(**)and~<

0.001

(~**).
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Acute Tolerance Effect Induced by DYN 1-13 on the GPI When Using Cumulative Method.
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Table XXI.

Acute Tolerance Effect Induced by DYN 1- 131 on the GPI.

Inhibition of
Electrically- Stimulated
Contractions (%)2

Significance
Relative to 0 time

Time
(min)

N

0

6

56.8 ± 1. 8

30

6

48.1 ± 2.9

<0.05

60

6

42.5 ± 4.2

<O.Ol

100

6

39.9 ± 2.0

<0.001

130

6

30.6 ± 2.9

<0.001

iconcentration of DYN i - 13 used at all the times was 1.2 ~~.
2Results are expressed as Mean ± S.E.

..E

DISCUSSION
The observation that substituted aminotetralins have the potential
for opioid agonist (Kandeel and Martin, 1973) as well as opioid
antagonist activity has stimulated the synthesis and pharmacological
evaluation of two new derivatives of 3- amino- 2,2- dimethyltetralin (J and
MRSAL).

These compounds were studied for opioid agonist and antagonist

capacity using the electrically-stimulated GPI and MVD preparations.
Other investigators (Paton, 1957; Waterfield et al., 1977; Henderson et
al., 1972) have demonstrated that the cholinergic junctions of the
myenteric plexus of the GPI and the adrenergic transmission of the
are depressed by opioid agonists.

l~

The present study has confi rmed that

these isolated tissues are very sensitive to opioid actions and are very
suitable for documenting the basic pharmacological properties of
potential narcotic analgesics, such as their receptor affinity (potency)
and their intrinsic activity (capacity for agonist or antagonist
effects).

It has been observed (Kosterlitz and Waterfield, 1975; Creese

and Snyder, 1975) that, in general, there is a very good correlation
between the relative agonist potency in GPI and the relative potency for
analgesia in humans.
Since these isolated tissue preparations have multiple opioid
receptors, it was also possible to study the opioid receptor specificity
of J and MRSAL.
The results of these experiments demonstrate that J has actions that

1~3
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qualitatively do not differ from those seen with other opioid agonists-J consistently caused a concentration- dependent decrease in contractions

in GPI and MVD and these effects could be antagonized by NX.

On the other hand, MRSAL demonstrated significant opioid antagonist
activity in a manner similar to that of NX.

The antagonism of MRSAL on

opioid receptors was specific, since it did not antagonize the inhibitory
effects of epinephrine in GPI.
The agonist properties of J and its receptor specificity were
studied by close examination of:

(~)

its relative potency to depress

contractions in the GPI as compared to the MVD; (ii) its sensitivity to
NX antagonism (analysis of Ke and pA 2 values) in both preparations; and
(iii) its selective blockade of B-FNA activated mu receptors in GPI.
Although these criteria are not completely satisfactory (mostly due to
lack of selective ligands), they have been widely used and have led to
the concept of multiple opioid receptors.

The observation that the

enkephalins are much more potent than morphine in the MVD but less potent
than this alkaloid in the GPI has led Lord et
enkephalins act on delta receptors in the MVD.

~.

(1977) to propose that

Furthermore, the apparent

dissociation constant (Ke value) of the opioid antagonist NX against mli
agonists is very low (2-5
(20-40

nM)

nM)

compared to that against kappa agonists

(See Tables XIII and XIV for references).

The Ke value may

not only be different in the same tissue (depending on which agonist is
being blocked) but also different between tissues.

For example, the

enkephalins have high pA2 values (Table XI) in the GPI suggesting
interaction at

~

sites in this preparation but lower values in the MVD

(Table XV) suggesting that here they bind to delta receptors (Lord et
al., 1977; Waterfield et al., 1977).

Selective~

receptor alkylation
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with B- FNA has demonstrated that normorphine, the enkephalins and
fentanyl are mg receptor agonists while dynorphin and EKC are preferentially~
(Schulz~

agonists in the GPI (Huidobro- Toro et al., 1982) and MVD

al., 1984).

Alkylation of mu, kappa and delta receptors with

B- CNA coupled with selective "protection" experiments have demonstrated
that B- endorphin is selective for

~

in the GPI but not selective for

~

over delta and kappa in the MVD (Goldstein and James, 1984) and that
dynorphin is kappa selective in guinea pig brain membranes

(James~

al.,

1982a,b).
The antagonist properties of MRSAL were evaluated by its capacity to
antagonize the decrease in contractions in GPI and MVD produced by
prototype agonists

of~'

kappa and delta opioid receptors.

Its potency

and selectivity for each of these agonists (Ke value) as well as its
affinity for each type of opioid receptor (pA2 value) were compared to
that of NX.
The results obtained in these experiments demonstrated that all of
the compounds tested showed some capacity to depress electrically- induced
contractions in both preparations.

All the reference opioids (NM, DHM,

EKC, U- 50,488H, BH- END, DYN 1- 13, Leu- ENK and DADLE) as well as the test
opioid (J) behaved as agonists in that they all caused a concentrationrelated decrease in the contractions and that this effect could be
antagonized by the nonselective opioid antagonist NX.

In the present

study, this reference opioid antagonist demonstrated poor agonist
capacity causing a decrease in contractions of only about 7% (352
an increase in contractions of about 3% (704

nM)

in GPI.

nM)

and

This poor

agoni st property of NX has also been reported by Kajiwara et al.,
(1986).

On the other hand, the test opioid antagonist, MRSAL, produced
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an increase in muscular contractions at virtually all concentrations
tested.

MRSAL could produce a decrease in contractions in GPI only at

high concentrations (850

~M).

This latter effect could be indicative of

an opioid agonist effect in this preparation but since no antagonism
experiment was done with NX, it is not possible to specify the
pharmacological receptor involved.

Since such a high concentration was

necessary to produce this effect, the experiment was not repeated.

It is

of interest to point out that this effect of decreasing contractions in
GPI could also be due to the activation of alpha and/or beta adrenergic
or dopaminergic receptors reflecting a non-opioid action.

Such activity

has been documented for several other aminotetralins (Cannon and Koble,
1980; Beaulieu et al., 1984; Cannon et al., 1980; DeMarinis et al.,
1982).

The increase in muscular contraction induced by MRSAL in the GPI

is presumably due to an increase in release of acetylcholine by the
postganglionic cholinergic nerves in the myenteric plexus.

It has been

well documented that opioid agonists inhibit release of acetylcholine in
the GPI (Schaumann, 1957; Paton, 1957; Huidobro-Toro et al., 1981b) and
in cerebral cortex (Jhamandas et al., 1977) and that this effect is
specifically antagonized by NX.

Furthermore, NX (30- 100

nM)

can cause an

increase in the output of acetylcholine released by electrical field
stimulation (0.017 Hz) in GPI (Waterfield and Kosterlitz, 1975) and rat
cerebral cortex (Jhamandas et al., 1977) .

It has been proposed that this

effect of NX is due to the blockade of endogenous enkephalins at the
cholinergic terminals within the myenteric plexus in the ileum (Waterfield
and Kosterlitz, 1975) and within the brain (Jhamandas et

~.,

1977).

could also increase the output of acetylcholine by antagonizing other
endogenous opioids such as dynorphin also present in the ileum.

These

NX
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observations suggest that endogenous opioids physiologically control the
release of acetylcholine from cholinergic neurons in the intestine.
Among all the opioid agonists tested, kappa prototypes (EKC,
U-50,488H and DYN 1-13) demonstrated an extremely high potency in the
GPI.

The fact that the myenteric plexus of the GPI is very sensitive to

kappa agonists is curious since there is as yet no information regarding
kappa binding sites in this preparation or in the MVD.

Except for DADLE,

kappa drugs were also the most potent agonists in the MVD preparation.
DADLE, a stable analog of Leu-ENK with reported delta receptor
selectivity, demonstrated extraordinary potency in the MVD.
is more potent than Leu-ENK in both preparations.

This peptide

The weak potency and

rapid actions of enkephalins in vitro and in vivo have been attributed to
their rapid degradation (Schwartz et al., 1981).

Three types of enzymes

(aminopeptidases, enkephalinase A and B) and also angiotensin-converting
enzyme may account for the hydrolysis of enkephalins (Gorenstein and
Snyder, 1979; Hudgin et al., 1981; Schwartz et al., 1981).

All of these

enzymes are found in brain tissue, and aminopeptidase activity is also
present in plasma and in the GPI (Schwartz et al., 1981).

The present

study has shown that not only Leu-ENK, but also DYN 1-13 and Bn-END,
spontaneously recover from inhibition to control contractions in
different rates (Tables XVIII-XX).

This spontaneous recovery of

inhibition is assumed to be due to peptide degradation and not to
tolerance at the receptor site since the preparation was still sensitive
to subsequent Leu-ENK and Bn-END, but not DYN 1-13.

The recovery rate to

control contractions did not increase with the development of tolerance
induced by DYN 1- 13.

The rate of spontaneous recovery varied among the

three opioid peptides--Leu-ENK was the fastest (66%) whereas BH-END was
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the slowest (13%) at 5 min.

The rate of spontaneous recovery is probably

influenced by several factors such as:

(~)

the qualitative and

quantitative distribution of the degradative enzymes in the tissue;

(li) the rate of dissociation of the peptide from its receptor, and
(iii) the size of the peptide molecule.
recovery of

B~END

explanations:

The slower rate of spontaneous

compared to that of Leu-ENK could have three possible

(1) the enzymes responsible for peptide degradation

present in the GPI are more specific for Leu-ENK than for BH-END;
(ii) the enzymes that degradate Leu-ENK are different from those that
hydrolyze BH-END, and (iii) the enzymes in the tissue produce active
metabolites with independent opioid agonist activity.

It should be noted

that in the BH-END molecule, the amino acid sequence 61-65 is Met-ENK,
61-76 is alpha-END and 61-77 is gamma-END and these all have opioid
agonist properties (Rossier and Bloom, 1979).

Sanchez-Blazquez

~t

al.

(1984a) reported a rate of spontaneous recovery of 59% for Leu-ENK and
51% for DYN 1-13 at 15 min.

In the present study, a much faster rate of

spontaneous recovery for both peptides was noted (see Tables XIX and
XX).

This difference could be due to the amount of protein/mg of tissue

which would vary depending on the length of the strip used (3-cm or
longer).
mg

We used a 3-cm long double strip forming a loop of 73.3 ± 1.6

(Mean± S.E., N = 70).

Slow and fast spontaneous recovery of

contractions after B-END and the enkephalins, respectively, have also
been described by Hughes (1975) and Cox et al. (1976).

It appears that

the rate of recovery occurs to differing extents in different ileum
preparations.
Morphine- induced tolerance in the GPI was first described by Paton
(1957) and confirmed by Gyang and Kosterlitz (1966).

Recently, Wuster et
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al. (1981a,b),

Schulz~

al. (1984) and Rezvani et al. (1983) have used

the development of tolerance induced by opiates to assess different
opioid receptor populations in the GPI and MVD.

The phenomenon that

DYN 1-13 induces acute tolerance in GPI has not yet been described in the
literature.

Tolerance induced by this peptide was time dependent but

independent of the concentrations of the peptide used or sequence of
administration to the bath.

Tolerance is usually measured as a decrease

in response to a given drug.

This phenomenon is not well understood and

can occur both in vitro and in vivo.

Tolerance induced by DYN 1-13 may

be due to a drug-induced change in conformation of the receptor to which
this peptide normally attaches.

This receptor may not be the same

receptor of EKC and U-50,488H because in DYN-tolerant preparations there
was no change in subsequent response to these opiates.
Phar-macological receptors have been traditionally identified and
classified according to their relative potencies and their sensitivity to
blockade by selective antagonists.

Different potencies in different

tissues by the same drug have established that the GPI has mainly
receptors whereas the MVD has predominantly delta receptors.

~

Potency of

a compound is dependent on its affinity for a specific receptor site and
on the number of specific receptors available in a tissue (Goldstein and
James, 1984).

Intrinsic activity of a compound depends on the relative

capacity to activate or not activate the tissue once the drug has
attached to its receptor.

Both affinity and intrinsic activity are

closely related to the chemical structures of the drug and its receptor.
The type of receptor and its population clearly can vary between
physiologically differentiated tissues, even when the same agonist is
used.
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Therefore, assuming that different potencies in different tissues
are indicative of different receptor populations, one can conclude:
(~)

Since the

~

agonists NM, DHM and BH-END are equipotent

in the GPI and MVD, they are acting at the same
receptor type in both preparations.
for the

~

This is also true

agonists EKC, U-50,488H and DYN 1-13.

Furthermore, since compound J is reasonably equipotent
in both preparations, this suggests that this agonist
interacts with the same receptor in both tissues and
lacks delta receptor activity in MVD.

In general, all

these agonists were slightly more potent in the GPI
than in the MVD.

This is probably explained by the

receptor reserve (Goldstein and James 1984) in these
two tissues.

Quantitatively (Creese and Snyder, 1975;

Leslie et al., 1980) and qualitatively (Lord et al.,
1977; Waterfield et al., 1977), there are
receptors in the GPI than in the MVD.
predominantly contains delta receptors.

more~

The MVD
The kappa

receptor population may be slightly less in the MVD
than in GPI.
(jJJ

The very high potency of Leu-ENK in the MVD suggests
that this peptide interacts with two different receptor
populations in these two tissues.

Leu-ENK and DADLE

have greater affinity for the delta receptors present
in the MVD than for the

~

receptors present in the GPI.

Concentration-response curves give important information not only
about the potency (affinity) but also about the intrinsic activity
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(efficacy) of an agonist.

Analysis of the regression lines in regard to

slopes and maxima indicate differences between the agonists in the GPI
and MVD.

All the compounds tested behaved as strong agonists, but the

opioid peptides, especially DADLE in the MVD, were the strongest agonists
(slope

= 60.5)

demonstrating high affinity and intrinsic activity at the

receptor site.
(slope

= 55.2)

Interestingly, NM was a more efficient agonist in the MVD
than in the GPI (slope

= 38.6).

All opioid agonists

caused a near maximum inhibition (70-90%) in both tissues.

The opioid

peptides and synthetic alkaloids NM and DHM had the highest intrinsic
activity.

An interesting exception was Leu-ENK in the GPI.

This lack of

maximum response by Leu-ENK is probably due to rapid degradation of the
peptide in this preparation, since its stable analog, DADLE, was able to
produce 90% maximum response in GPI.
Despite its low potency, compound J was capable of producing a
maximum response comparable to Leu-ENK and U-50,488H in the GPI and
BH-END and DYN 1-13 in the MVD.
The simple observation that a particular agonist is capable of
producing a pharmacological effect does not give any information as to
which receptor type is involved to produce that effect.

Therefore, the

use of highly selective antagonists is extremely important in receptor
differentiation.

Unfortunately, presently available opioid antagonists

are only "sufficiently" selective.

Although NX is more selective for

receptors, it is highly unselective for kappa and delta sites.
relative affinity of NX

for~

~

The

sites is 0.85, for kappa 0.06 and delta

0.09 in brain homogenates (Paterson et al., 1984).

It is expected that a

"selective" antagonist should have an affinity for a specific site at
least 100 to 1000 times over its affinity for some other site.

Despite
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the fact that NX is not a selective antagonist, it has been widely used
to characterize multiple opioid receptor selectivity.

The use of

antagonists to differentiate the opioid receptor selectivity of an
agonist is based on the fundamental assumptions of classical receptor
theory.

If two agonists are acting at the same receptor site, they

should have the same pA 2 value (or Ke) for a reference antagonist.

In

contrast, if the pA 2 value for a common antagonist is different for two
different agonists, this means that these two agonists interact with
different receptors (Arunlakshana and Schild, 1959).

Therefore, the pA2

value (or Ke) measures the affinity of the antagonist for the receptor of
the test agonist.
The different pA 2 (or Ke) values for NX suggests that DYN 1-13 is an
endogenous kappa ligand since the Ke value for NX against this peptide is
similar to that against cyclazocine and EKC (Chavkin et al., 1982;
Yoshimura et al., 1982a; Huidobro-Toro et al., 1982).

However, this

peptide demonstrates kappa agonist activity only in vitro and not in vivo
(Lee, 1983).
The analysis of the pA2 values for NX and MRSAL against all the
reference opioids was not a simple task.

Both compounds demonstrated

different antagonistic potencies and affinities for each agonist and
varied between the two tissues used.
In the GPI,

~

agonists NM, DHM and the delta agonist

all very sensitive to NX antagonism.

Leu-E~~

were

The high pA2 (and low Ke) value for

Leu-ENK indicates that in this preparation this peptide activates mg
receptors.

A comparison of the pA2 for NX against J indicates that J is

an agonist at the same receptor occupied by DHM,
mg agonists in the GPI).

B~END

and Leu-ENK (all

This strongly suggests that J is active at mg
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receptors.

However, the small, but significant, difference between the

pA 2 for NX against NM and DADLE versus J is unexplainable (Table XII),
since these opioids are also mu agonists in the GPI.
A greater difference was seen with the kappa versus
making these experiments easier to analyze.

~

agonists

EKC, U- 50,488H and DYN 1-13

had pA2 values for NX antagonism that were indistinguishable from each
other suggesting that these agonists act at a common receptor.

Since NX

has lower affinity for kappa receptors, it is suggested that these
agonists are acting at this site.

The highly significant difference

between NX pA 2 values against kappa agonists and J indicates that J is
not acting on a

~

receptor in the GPI.

J seems to fall in a class of

"intermediate" pA2 (NX) values like BH- END and DADLE.

It should be noted

that higher pA 2 values for NX antagonism of BH-END and DADLE have been
reported (Table XIV).
In the MVD, the picture for pA2 analysis was even more complicated.
This is probably due to the presence of at least three opioid receptors
(delta, kappa

and~)

antagonists.

However, it was clear that NX had its highest affinity at

DHM, NM

(~)

and the lack of specificity of agonists as well as

and J receptor.

There was no significant difference between

NX pA2 values against J and NM.
appears that J is a

~

Since this was not the case with DHM, it

agonist like NM but not like DHM.

It also seems

that in this preparation, J falls in a class of compounds with
"intermediate" pA2 values.

This suggests that J is primarily a

~

receptor agonist but also may have some actions at kappa sites.
All the other reference opioid agonists were much less sensitive to
NX antagonism in the MVD.

This includes the kappa agonists (U- 50,488H,

DYN 1- 13 and EKC) and delta agonists (DADLE and Leu- ENK) and BH- END.

In
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this preparation, BH-END is an agonist at mu and delta and possible kappa
sites, whereas DADLE and Leu-ENK are specific delta agonists.

Also,

kappa agonists U-50,488H, DYN 1-13 and EKC act in the MVD in a manner
similar to that in the GPI.
Discrimination of receptors based on NX antagonism (either from Ke
or pA2 values of NX) may provide misleading information concerning the
receptor selectivity of an agonist due to the presence of multiple
receptor populations in different tissues.

It is well recognized that NX

is not mg specific and also has affinity for kappa and delta (and epsilon
and sigma) receptors in higher concentrations.

In addition, the lack of

receptor selectivity of most agonists further complicates the interpretation of Ke or pA2 values of NX.
(jj

Two illustrative examples are:

Based on sensitivity of antagonism by NX, both EKC
and DYN 1-13 are grouped together as kaooa agonists.
However, Wuster et al. (1981a,b) have demonstrated
that DYN 1-13 displays greater cross-tolerance to MRZ
2549 (kappa agonist) than to EKC.

This is probable

because EKC also has strong mg affinity in addition
to its kappa receptor affinity.

In fact, Goodman and

Pasternak (1984) have noted that EKC binds with high
affinity to the

~

1 site, and unlabeled EKC is able

to displace~ (3H-DHM) and delta (3H-DADLE) with
the same potency as [3H]-EKC.

This suggests that at

least in brain tissue, EKC is capable of interacting
with

~'

kappa and maybe delta sites.

Although these

same experiments were not done in GPI and MVD
tissues, it is possible that the same situation
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occurs, since these tissues also have mg, kappa and
delta receptors.

A s i milarity between mg and delta

bi nding sites in these isolated preparations and
receptors in the brain has been observed (Leslie et
al., 1980; Creese and Snyder, 1975).

In the present

study it was documented that EKC also has mg
properties in the GPI, since its effects were
significantly

(f < 0.01,

B-FNA treatment.

Fig. 11) antagonized by

Thus, EKC

has~

and kappa

properties in GPI and probably also in MVD, whereas
U- 50,488H and DYN 1- 13 are better kappa agonists.
However, all have indistinguishable pA2 values for NX
antagonism.
(ii)

One way to illustrate that NX pA2 value can be
misleading is to characterize the receptor preference
for

B~END.

In the GPI, the Ke value for NX

antagonism against this peptide suggests an
interaction at mg sites; however, in the MVD (a lower
pA2 value) it appears that this peptide is acting on
receptors different from mu.
been shown that

BH- E1~

In actuali ty, it has

is not selective for mg over

delta or kappa in MVD by the use of alkylating
experiments with B- CNA (Goldstein and James, 1984).
In MVD, the pA2 value for NX antagonism of BH- END is
lower than that

for~

(therefore, BH- END is not mg)

and it is of the magnitude as those for delta and
kappa agonists (see Table XV).
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Furthermore, based on the pA 2 values of NX against morphine,
ketocyclazocine and SKF- 10,047, Su and co-workers (1981) concluded that
the GPI also has sigma opioid receptors.

These investigators further

pointed out that the evidence for differentiation of

~

and sigma

receptors is not as strong as the differentiation of these receptors
from~

sites.

Finally, Kajiwara et al. (1986) concluded that

buprenorphine is an agonist on both

~

and kappa receptors because the

Ke value of NX against this opioid lies in between those against
those against

~

~

and

agonists.

All these observations suggest that pA2 and Ke values for NX may
predict whether a compound is preferentially a

~

agonist by the simple

demonstration of very high pA2 and very low Ke values (high affinity).
However, when the preparation has all three receptors sites, calculation
of pA 2 values for NX may not explain the receptor selectivity of an
agonist because the interpretation of the Ke value (Kosterlitz and Watt,
1968) is based on the assumption that an agonist acts on a single
receptor type.

Intermediate pA2 and Ke values can only suggest that

either the putative agonist is acting simultaneously at

~

and kappa

and/or delta receptors, or that the agonist is acting on a single,
not-yet-identified receptor (Schulz et al., 1984).

Arunlakshana and

Schild (1959) recognized these complications and pointed out that "it is
not known how far the principle of classifying agonists by their pAx can
be extended; it tends to break down ••• when applied to agonists with
an indirect action."
In spite of this controversy, the pA2 and Ke values for MRSAL
antagonism against reference and test opioid agonists were calculated.
Like NX, this antagonist showed different degrees of potency and affinity
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for the different opioi d receptors, but it is clearly not as potent an
antagonist as NX.

However, despite its low affinity, MRSAL was a full

antagonist of opioid receptors.
receptors.

Its highest affinity was seen at

In the GPI, the highest pA 2 and lowest Ke values for MRSAL

antagonism was seen at

~

receptors.

The order of affinity and

antagonistic potency in the GPI was Leu-ENK > DHM > NM >
(all~

~

agonists in this preparation).

B~END

> DADLE

On the other hand, MRSAL had

lower affinity at kappa receptors, since lower pA2 values were obtained
for EKC and U-50,488H -- but not for DYN 1-13.

Interestingly, this

antagonist (in contrast to NX) demonstrated higher affinity for DYN 1-13
than for EKC and U-50,488H receptors.

This low Ke value was not expected

since DYN 1-13 behaves like a kappa agonist (Goldstein, 1984) in isolated
tissues.

This great difference in antagonistic potency (Ke values, Table

XVII) against DYN 1-13 compared to that against EKC and U- 50;488H may
suggest that either DYN 1-13 has mu actions or is acting on a different
receptor site from EKC and U-50,488H in the GPI.

Since the pharmacology

of DYN 1-13 does not completely agree with that predicted for true kappa
agonists (Lee, 1983), it is possible that the receptor site for DYN 1-13
is not quite the same as that for the classic kappa drugs.

MRSAL had intermediate Ke and pA2 values against J.
indicate that while J preferentially has

~

This may

actions, i t is also able to

stimulate other receptors (kappa?).

It could also indicate that MRSAL is

simply not very selective for either

~

or kappa receptors in the GPI.

In the MVD, MRSAL demonstrated lower antagonistic potency than in
the GPI, but its highest affinity was also seen at
values were seen against DHM, NM and J.

~

sites.

Highest Ke

MRSAL's pA2 values against these

agonists were above 5.0, whereas those against kappa and delta prototypes
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were lower,

The kappa agonists had intermediate pA2 and Ke values for

MRSAL antagonism, whereas the delta prototypes had extremely low values
(pA2

~.05- ~.11).

The experiments with MRSAL suggest that this antagonist has its
highest affinity at mli receptors, intermediate affinity when antagonizing
kappa agonists and low affinity at delta sites,
MRSAL antagonism supports the argument that J is primarily a mli
agonist, since this antagonist demonstrated comparable antagonist
potencies against NM, DHM and J in the MVD.

In the GPI, however, the

antagonist capacity of MRSAL against J was lower than that expected for a
mli agonist.

Further delineation of receptor selectivity of MRSAL needs

to be done using competitive displacement of selectively labeled opioids
in GPI, MVD and brain membranes.
MRSAL has been tested in vivo for analgesic activity using the mouse
tail-flick and phenylquinone-writhing tests by Dr. M. D. Aceto (NIH,
1985, personal communication),

This compound was inactive at doses up to

30 mg/Kg in the tail-flick assay, but demonstrated analgesic activity in
the writhing assay (ED 50
limits).

= 21.9

mg/Kg; 6.8- 70.8

= 95%

confidence

It should be noted that this latter assay is more specific for

the non-narcotic analgesics (aspirin, phenylbutizone, propoxyphene, etc.)
than for the narcotic analgesics.

As an antagonist of morphine in the

mouse tail-flick assay MRSAL produced the following results:

At a dose

of 1 mg/Kg, MRSAL caused a 6% antagonism of morphine analgesia; at 3
mg/Kg, 10%; at 10 mg/Kg, 37% and at 30 mg/Kg,
were not used.

~3%.

Higher concentrations

These data indicate that MRSAL is a true pharmacologic

antagonist of morphine analgesia and may block this alkaloid through some
action on mli receptors,
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To further delineate the receptor specificity involved in the
agonist effects of J, B-FNA was used for the specific purpose of
inactivating

~

receptors.

This technique should provide convincing

evidence whether or not an agonist is selective for

~

receptors.

B-FNA

has reversible agonist effects antagonized by NX with pA 2 values similar
to those of mixed agonist-antagonists (nalorphine, pentazocine) and EKC.
Therefore, Takemori et al. (1981) and Takemori and Portoghese (1985a)
concluded that B-FNA is a reversible kappa agonist.

As an antagonist,

this agent has been reported to irreversibly antagonize morphine, NM,
enkephalins and its analogs in the GPI and morphine, NM and
agonists in the MVD.

other~

However, Smith et al. (1984) have noted that B-FNA

(1o-8 and 1o-7M) blocks the effects of agonists on mg (morphine),~
(MR-2033) and delta (DSLET, an enkephalin analog) receptors in the MVD.
In our experiments, B-FNA pretreatment irreversibly antagonized NM,
Dffi1 and J, while EKC was only partially blocked (Fig. 11).

There was

approximately a 90% blockade of the agonist effects of J in the GPI.
These data further indicate that NM and DHM are acting on
and that J behaves like

a~

agonist in GPI.

residual effect (10%) on either
inactivated by B-FNA or

on~

some~

~

receptors

Nevertheless, J may have a

receptors (spare receptors?) not

receptors.

NX was used in low

concentrations (176 nM) and it was able to antagonize the residual effect
of J by 98%.

This may indicate that

some~

receptors were still

available and J was able to interact with them.
~sites

These B-FNA "insensitive"

have been described by Takemori and Portoghese (1985b).

The fact that B-FNA also caused significant antagonism of EKC
effects strongly supports the data of others that EKC also has
in the GPI.

~

actions
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Finally, J has been shown to exert true morphine-like analgesic
activity in vivo.

In the mouse tail-flick assay, J was analgesic

intraperitoneally (ED 50

= 6.2

mg/Kg; 2.2-17.6

= 95%

and almost equipotent to morphine sulfate (ED 5o
95% confidence limits).

confidence limits)

= 5.8

mg/Kg; 5.7-5.9

=

In the phenylquinone writhing test, this

compound produced analgesia at 9.9 mg/Kg dose intraperitoneally.
Surprisingly, J was inactive in the mouse hot-plate assay at doses of 5
and 20 mg/Kg.

Like the tail-flick procedure, this assay is relatively

specific for morphine-like analgesics,

When tested using the Single Dose

Substitution (SDS) procedure in morphine-dependent monkeys, J produced a
linear dose-response related to a decrease in withdrawal signs.

This

procedure is considered to be highly specific for morphine-like activity.
Doses ranged from 1.5- 12 mg/Kg.

However, J was not able to totally

suppress the withdrawal syndrome (Dr. M. D. Aceto, NIH, 1985, personal
communication).

J at 30 mg/Kg intraperitoneally did not antagonize

morphine in the mouse tail-flick assay.

These data demonstrate that J is

an analgesic agonist of comparable potency to that of morphine in the
tail-flick assay and that it lacks significant opioid antagonist
capability.

The fact that J is able to suppress (at least in part)

morphine withdrawal symptoms in SDS monkeys further supports the
conclusion that J is primarily a

~

agonist,

Kappa agonists are

analgesics but do not suppress morphine abstinence (Martinet al.,
1976).

Taken all together, these data suggest that J is

a~

agonist in

vitro and in vivo and has narcotic analgesic properties similar to
morphine.
Since there are no specific opioid antagonists, a very specific test
to demonstrate that J is a

~

agonist would be to demonstrate cross-
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tolerance to morphine in vitro using the method of Rezvani et al.
(1983).

The principle of this method lies on the assumption that if two

or more opioids exhibit complete cross-tolerance, they must be acting at
identical receptors.

CONCLUSIONS
The purpose of this research was to characterize the opioid effects
and the receptor selectivity of two new aminotetralin derivatives, J and
MRSAL, using the electrically-driven GPI and MVD preparations.
Our studies demonstrated that J behaved as an opioid agonist in
that it consistently depressed electrically-induced contractions in a
concentration-dependent manner and its effects could be antagonized by
NX.

On the other hand, MRSAL demonstrated significant and specific

opioid antagonist capacity in a manner similar to NX.

This antagonist

was effective whether it was pre-incubated or added after the reference
opioid agonists (NM, DHM, EKC, U-50,488H, BH-END, DYN 1-13, Leu-ENK and
DADLE).

Compound MRSAL was also able to antagonize its keto-analog, J.

The opioid receptor selectivity of these two aminotetralins was
studied.

Compound J seems to be an opioid agonist with

preference because:

(~)

~

receptor

J was equipotent in GPI and MVD and, therefore,

did not act on delta sites in MVD; (ii) the effects of J were completely
and reversibly antagonized by low concentrations of NX in both tissues;
(iii) the agonist activity of J was irreversibly blocked by B-FNA
pretreatment in GPI; and (iv) in antagonist experiments with its alcohol
analog MRSAL, J was antagonized by MRSAL with comparable potency and
affinity to that of NM and DHM.
The opioid antagonist, MRSAL, demonstrated its highest affinity for
~

receptors and was able to effectively antagonize NM and DHM in both
162
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GPI and MVD.
over~

Like

~~,

MRSAL appeared to be somewhat selective for mu

receptors, but poor affinity was seen at delta sites in MVD.

In contrast to NX, MRSAL demonstrated better antagonist potency for
DYN- 13 than for EKe and U-50,488H in GPI, suggesting that this peptide
may act on a site different from that of EKe and U-50,488H.
The findings of the present study are important in that they relate
the chemical structures of these compounds with their pharmacological
effects.

These aminotetralins demonstrated that a slight modification

in the molecular structure of compound J (an agonist) resulted in a new
molecule (MRSAL) now possessed with antagonist activity.

Both

compounds, the keto (J) as well as its alcohol analog (MRSAL), were able
to interact with opioid receptors.
The manner by which synthetic and endogenous narcotic analgesics
interact with opioid receptors is not well known, but based on the

chemical structures of clinically active compounds, several opioid
receptor models have been proposed (Beckett and easy, 1954; Feinberg et
al., 1976; Portoghese et al., 1981; Lee and Smith, 1980; Martin, 1984).
The original model proposed by Beckett and easy (1954) stated that the
opioid receptor surface has three essential sites:

(~)

a flat area for

the binding of the aromatic ring of the narcotic compound; (ii) an
anionic site for interaction with the amine group; and (iii) a cavity.
This model described only one binding site for the different opiate
agonists.

The idea of a single binding site allosterically modulated by

sodium ions to an agonist or antagonist conformation has been advanced
by Feinberg et al. (1976) and others have proposed the presence of two
binding sites for interaction of morphine, enkephalins and beta- endorphin
(Lee and Smith, 1980; Portoghese

~

al., 1981; Martin, 1984).
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One common characteristic of all narcotic agonists and antagonists,
including the aminotetralins, is the presence of a flat aromatic ring
and an amine group in their molecular structure.

The chemical

requirements for the interaction of compounds J and MRSAL to opioid
receptors are present in their molecular structures.

The aromatic ring

would "fit" the flat surface while the tertiary amine should bind to the
anionic site of the opioid receptor.

However, the dramatic change in

pharmacological effects due to the relatively slight difference in
structure between compound J and MRSAL cannot be explained easily.

It

has been well accepted that the introduction of an allyl or cyclopropylmethyl group on the amine of morphine-type agonists usually confers
antagonist activity to the new compound (Feinberg et al., 1976; easy and
Parfitt, 1986).

MRSAL, the alcohol analog of J, lacks both an allyl or

cyclopropylmethyl group substitution.

Since the most significant

difference between J and MRSAL is the ketone versus alcohol function at

c1

position, our studies suggest that this modification may be very

critical pharmacologically.

It is possible that the interaction of

MRSAL with the receptor can change the amine orientation or the manner
of interaction of the aromatic ring to the receptor.
It would seem productive for chemists to modify further the
structures of these compounds, since new molecules with greater affinity
and specificity for opioid receptors may result.
As in the case of all unresolved molecules, there are multiple
isomeric forms of J and MRSAL.

Whereas with 3-(dimethylamino)-2,2-

dimethyl-7-hydroxy-1-tetralol, there can be both configurational and
optical isomers.
isomer.

MRSAL was comprised of a racemic mixture of the cis

The other configurational isomer, the trans form (RMG), was
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isolated as a racemate, and was also tested in the GPI preparation.

In

contrast to MRSAL, RMG showed agonist activity which was partially
reversed by NX and MRSAL.

RMG also exhibited poor antagonist activity

towards NM, DHM and DADLE (Lippman et al., 1987).

Therefore, the opioid

antagonist activity of MRSAL was due to the cis configurational isomer
rather than the trans isomer.
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